<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012211490
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Midathetic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MIDAZOLAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Amoun Pharmaceutical Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Amoun Pharmaceutical Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 467]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Thimar Aljazirah Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                             Amoun Pharmaceutical Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05CD08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Midathetic belongs to a group of medicines called &#39;benzodiazepines&#39;. Midathetic works quickly to make you feel sleepy or to put you to sleep. It also makes you calm and relaxes your muscles.</p><p>Midathetic is used in adults:</p><p>&bull; as a general anesthetic to put them to sleep or to keep them asleep.</p><p>Midathetic is also used in adult&amp; and children:</p><p>&bull; to make them feel calm and sleepy if they are In Intensive care. This Is called &#39;sedation&#39;.</p><p>&bull; before and during a medical test or procedure where they are going to stay awake. It makes them feel calm and sleepy. This Is called &#39;conscious sedation&#39;.</p><p>&bull; to make them feel calm and sleepy before they are given an anesthetic.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Midathetic:</strong></p><p>&bull; if you are allergic to midazolam or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; if you are allergic to other benzodiazepine medicines, such as diazepam or nitrazepam.</p><p>&bull; if you have severe breathing problems and you are going to have Midathetic for conscious sedation.</p><p>You must not be given Midathetic If any of the above applies to you. If you are not sure, talk to your doctor or nurse before you are given this medicine.</p><p><strong>warnings and precautions</strong></p><p><u>Talk to your doctor or nurse before you are given Midathetic:</u></p><p>&bull; if you are over 60 years of age.</p><p>&bull; if you have a long-term illness, such as breathing problems or kidney, liver or heart problems.</p><p>&bull; if you have an illness that makes you feel very weak, run down and short of energy.</p><p>&bull; if you have something called &#39;myasthenia gravis&#39; where your muscles are weak.</p><p>&bull; if you have a condition called &#39;sleep apnea syndrome&#39; (where your breathing stops when you are asleep.</p><p>&bull; if you have ever had alcohol problems.</p><p>&bull; if you have ever had drug problems.</p><p><u>If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Midathetic.</u></p><p><strong>Children</strong></p><p>&bull; Talk to your doctor or nurse if any of the above applies to your child.</p><p>&bull; In particular, tall your doctor or nurse if your child has heart or breathing problems.</p><p><strong>Other medicine and Midathetic</strong></p><p>Tell your doctor or nurse If you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines.</p><p>This is because Midathetic can affect the way some other medicines work. Also some&nbsp; other medicines can affect the way Midathetic works.</p><p>In particular, <u>tell your doctor or nurse if you are taking any of the following medicines:</u></p><p>&bull; Medicines for depression (antidepressants)</p><p>&bull; Hypnotic medicines (to help you sleep)</p><p>&bull; Sedatives (to make you feel calm or sleepy)</p><p>&bull; Tranquillizer medicines (for anxiety or to help you sleep)</p><p>&bull; Carbamazepine or phenytoin (these may be used for fits or seizures)</p><p>&bull; Rifampicin (for tuberculosis)</p><p>&bull; Medicines for HIV and Hepatitis C called &#39;protease inhibitors&#39; (such as saquinavir, boceprevir, telaprevir)</p><p>&bull; Antibiotics called &#39;macrolides&#39; (such as erythromycin or clarithromycin)</p><p>&bull; Medicines to treat fungal infections (such as ketoconazole, voriconazole, fluconazole, itraconazole, parconazole)</p><p>&bull; Strong pain killers</p><p>&bull; Atorvastatin (for high cholesterol)</p><p>&bull; Antihistamines (for allergic reactions)</p><p>&bull; St John&#39;s Wort (a herbal medicine for depression)</p><p>&bull; Medicines for high blood pressure called &#39;calcium channel blockers&#39; (such as diltiazem} If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Midathetic.</p><p>Concomitant use of Midathetic and opioids (strong pain killers, medicines for substitution therapy and some cough medicines) increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening.</p><p><u>Because of this, concomitant use should only be considered when other treatment options are not possible.</u></p><p>However, if your doctor does prescribe Midathetic together with opioids the dose and duration of concomitant treatment should be</p><p>limited by your doctor.</p><p>Please tell your doctor about all opioid medicines you are taking, and follow your doctor&#39;s dose recommendation daily. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.</p><p><strong>Midathetic with alcohol</strong></p><p>Do not drink alcohol if you have been given Midathetic. This is because it may make you feel very sleepy and cause problems with your breathing.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Talk to your doctor before you are given Midathetic if you are pregnant or think you may be pregnant. Your doctor will decide if this medicine Is suitable for you.</p><p>After you have been given Midathetic, do not breast-feed for 24 hours. This is because Midathetic may pass into your breast milk.</p><p><strong>Driving and using machines</strong></p><p>After having Midathetic, do not drive or use tools or machines until your doctor says you can. This Is because Midathetic may make you feel sleepy or forgetful. It may also affect your concentration and coordination. This may affect you being able to drive or use tools and machines. After your treatment, you must be taken home by an adult who can look after you.</p><p>The medicine can affect your ability to drive as it may make you sleepy or dizzy.</p><p>Do not drive while taking this medicine until you know how it affects you.</p><p>It is an offence to drive if this medicine affects your ability to drive.</p><p>However, you would not be committing an offence if:</p><p>The medicine has been prescribed to treat a medical or dental problem and You have taken It according to the instructions given by the prescriber or in the information provided with the medicine and It was not affecting your ability to drive safely</p><p>Talk to your doctor or pharmacist if you are not sure, whether it is safe for you to drive while taking this medicine.</p><p><strong>Midathetic contains sodium</strong></p><p>This medicine contains very small amount of sodium, that is to say essentially &ldquo;sodium&middot; Free&rdquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Midathetic will be given to you by a doctor or nurse. It will be given to you in a place that has the equipment needed to monitor you and to treat any side effects. This might be a hospital, clinic or doctor&#39;s surgery. In particular, your breathing, heart and circulation will be monitored.</p><p>Midathetic is <u>not recommended </u>for use in infants and babies under 6 months of age.</p><p>However, if the doctor feels that it is necessary, it can be given to an infant or baby under 6 months who is in intensive care.</p><p><strong>How Midathetic will be given to you</strong></p><p><u>You will be given Midathetic in one of the following ways:</u></p><p>&bull; By slow injection into a vein (intravenous injection).</p><p>&bull; Through a drip into one of your veins (intravenous infusion).</p><p>&bull; By injection into a muscle (intramuscular injection).</p><p><strong>How much Midathetic will be given to you?</strong></p><p>The dose of Midathetic varies from one patient to another. The doctor will work out how much to give you. It depends on your age, weight and general health. It also depends on what you need the medicine for, how you respond to treatment, and whether you are going to be given other medicines at the same lime.</p><p><strong>After being given Midathetic</strong></p><p>After your treatment. you must be taken home by an adult who is able to look after you. This is because Midathetic may make you sleepy or forgetful. It may also affect your concentration and coordination. If you are given Midathetic for a long time, such as in intensive care, your body may start to gat used to the medicine. This means it may not work as well. If you are given more Midathetic than you should Your medicine will be given to you by a doctor or nurse. This means It Is unlikely that you will be given too much. However, <u>if you are given too much by mistake, you may notice the following:</u></p><p>&bull; Feeling sleepy and losing your co-ordination and reflexes.</p><p>&bull; Problems with speaking and unusual aye movements.</p><p>&bull; Low blood pressure. This may make you feel dizzy or light-headed.</p><p>&bull; Slowing or stopping of your breathing or heart beat and being unconscious (coma).</p><p><u>Long term use of Midathetic for sedation In Intensive care If you are given Midathetic for a long time, the following may happen:</u></p><p>&bull; It may start to work less well.</p><p>&bull; You may become dependent on the medicine and get withdrawal symptoms when you stop having it (see &quot;Stopping Midathetic below). If use of Midathetic Is stopped</p><p>If you are given Midathetic for a long time, such as in intensive care, <u>you may get withdrawal symptoms when you stop being given the medicine.</u></p><p><u><strong>Mood changes</strong></u></p><p>&bull; Fits (convulsions)</p><p>&bull; Headache</p><p>&bull; Diarrhoea</p><p>&bull; Muscle pain</p><p>&bull; Problems with sleeping (insomnia)</p><p>&bull; Feeling very worried (anxious), tense, restless, confused or bad tempered (irritable).</p><p>&bull; Seeing and possibly hearing things that are not really there (hallucinations).</p><p>Your doctor will lower your dose gradually. This will help to stop withdrawal symptoms from happening to you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects have been reported but their frequency is not known and cannot be estimated from the available data.</p><p><strong>Stop having Midathetic and see a doctor Straight away if you notice any of the following side effects. They can be life-threatening and you may need urgent medical treatment:</strong></p><p>&bull; A severe allergic reaction (anaphylactic shock). The signs may include a sudden rash, Itching or lumpy rash {hives) and swelling of the face, lips, tongue or other parts of the body. You may also have shortness of breath, wheezing or trouble breathing.</p><p>&bull; Heart attack (cardiac arrest). The signs may include chest pain.</p><p>&bull; Breathing problems. sometimes causing the breathing to stop.</p><p>&bull; Muscle spasm around the voice box, causing choking.</p><p><u>Life-threatening side effects are more likely in Adults over 60 years, and in people who already have breathing or heart problems. These side effects are also more likely if the injection is given too fast or at a high dose.</u></p><p><strong>Other possible side effects Nervous system and mental problems</strong></p><p>&bull; Being less alert</p><p>&bull; Feeling confused</p><p>&bull; Feeling very happy or excited (euphoria).</p><p>&bull; Changes in libido</p><p>&bull; Feeling tired or sleepy or being sedated for a Long time.</p><p>&bull; Seeing or possibly hearing things that are not really there (hallucinations).</p><p>&bull; Disturbance of consciousness (delirium)</p><p>&bull; Headache</p><p>&bull; Feeling dizzy</p><p>&bull; Difficulty coordinating muscles</p><p>&bull; Fits (convulsions) in premature and new-born babies.</p><p>&bull; Temporary memory loss. How long this last depends on how much Midathetic you were given. Occasionally this has lasted for a long Ume.</p><p>&bull; Feeling agitated, restless, angry or aggressive.</p><p><u>You may also have muscle spasms or shaking of your muscles that you cannot control (tremors). These effects are more likely if you have been given a high dose of Midathetic or if it has been given too quickly. It is also more likely in children and elderly people.</u></p><p><strong>Heart and circulation</strong></p><p>&bull; Fainting</p><p>&bull; Slow heart rate</p><p>&bull; Redness of the face and neck (flushing)</p><p>&bull; Low blood pressure. This may make you feel dizzy or light-headed. Breathing</p><p>&bull; Hiccups</p><p>&bull; Being short of breath Mouth, stomach and gut</p><p>&bull; Dry mouth</p><p>&bull; Constipation</p><p>&bull; Feeling sick (nausea) or being sick (vomiting)</p><p><strong>Skin</strong></p><p>&bull; Feeling itchy</p><p>&bull; Rash, including a lumpy rash (hives)</p><p>&bull; Redness, pain, blood clots or swelling of the skin where the injection was given.</p><p><strong>General</strong></p><p>&bull; Allergic reactions including skin rash andwheezing.</p><p>&bull; Swelling of the skin/mucous membrane (angioedema)</p><p>&bull; The risk of falls and fractures is increased in those taking concomitant sedatives (Including alcoholic beverages)</p><p>&bull; Withdrawal symptoms (see &#39;Stopping Midathetic In Section 4 above)</p><p>&bull; Drug abuse</p><p><strong>Elderly people</strong></p><p>&bull; Older people taking benzodiazepine medicines, like Midathetic, have a higher risk of falling and breaking bones.</p><p>&bull; Life-threatening side effects are also more likely to happen in adults over 60 years.</p><p>&nbsp;</p><p><u>Reporting of side effects If you get any side effects, talk to your doctor or nurse: This includes any possible side effects not listed in this leaflet</u></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>Email: NPC.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Your doctor or pharmacist is responsible for storing Midathetic. They are also responsible for disposing of any unused Midathetic correctly.</p><p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the label/carton after</p><p>&quot;EXP:&quot;. The expiry date refers to the last day of that month.</p><p>&bull; Do not use this medicine if the small glass bottle (ampoule) or packaging is damaged.</p><p>&bull; Stored at temperature not exceeding 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>For Midathetic&reg; 3 ml:</u></p><p>Carton Box contains 3 amber glass ampoules (Type I), each of 3 ml with insert leaflet</p><p><u>For Midathetic&reg; 1 ml:</u></p><p>Carton Box contains 1 or 10 amber glass ampoules (Type I) , each of 1 ml with insert leaflet</p><p>&nbsp;</p><p><strong>&nbsp;Special precautions for disposal</strong></p><p>Compatible with the following solutions for infusion</p><p>&minus; 0.9% Nacl</p><p>&minus; 5% Dextrose</p><p>&minus; 10% Dextrose</p><p>&minus; Ringer Saline</p><p>The solution for injection should be examined visually before administration. Only solutions without visible particles should be used.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                N/A
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amoun Pharmaceutical Company</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                N/A
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي عقار ميداثيتيك لفئة من الأدوية يُطْلَق عليها &quot;البنزوديازيبينات&quot;. يبدأ مفعول ميداثيتيك سريعًا حيث يجعلك تشعر بالنعاس أو تنام. كما يساعدك على الشعور بالهدوء واسترخاء العضلات.</p><p dir="RTL">استخدام ميداثيتيك مع الكبار:</p><p dir="RTL">&bull; يُسْتَخْدَم هذا العقار كمخدر عام لمساعدتهم على النوم أو للحفاظ على نومهم.</p><p dir="RTL">استخدام ميداثيتيك مع الكبار والأطفال:</p><p dir="RTL">&bull; يُسْتَخْدَم هذا العقار في وحدات الرعاية المركزة ليساعدهم على الشعور بالهدوء والنعاس، وهو ما يُعْرَف باسم &quot;التهدئة&quot;.</p><p dir="RTL">&bull; يُسْتَخْدَم هذا العقار قبل أو أثناء عمل فحوصات طبية تستدعي كونهم في حالة يقظة؛ حيث يساعدهم هذا العقار على الشعور بالهدوء والنعاس، وهو ما يُعْرَف باسم &quot;التهدئة الواعية&quot;.</p><p dir="RTL">&bull; يُسْتَخْدَم هذا العقار لمساعدتهم على الشعور بالهدوء والنعاس قبل إعطائهم مخدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يُنْصَح بتناول ميداثيتيك في أي من الحالات الآتية:</p><p dir="RTL">&bull; إذا كنت تعاني من حساسية لميدازولام أو أي من المكونات الأخرى لهذا العقار.</p><p dir="RTL">&bull; إذا كنت تعاني من حساسية لأي من أدوية البنزوديازيبينات الأخرى مثل: ديازيبام أو نيترازيبام.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل شديدة في التنفس، وستتناول عقار ميداثيتيك من أجل &quot;التهدئة الواعية&quot;.</p><p dir="RTL">يجب عدم تناول ميداثيتيك إذا كان أي من الحالات السابقة تنطبق عليك. وفي حالة عدم التأكد، يمكنك استشارة طبيبك أو الممرضة الخاصة بك قبل تناول هذا العقار.</p><p dir="RTL">المحاذير والاحتياطات</p><p dir="RTL">تحدث إلى طبيبك أو الممرضة الخاصة بك قبل تناول ميداثيتيك في أي من الحالات الآتية:</p><p dir="RTL">&bull; إذا كنت قد تجاوزت الستين من عمرك.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض طويل الأمد: مثل قصور فى التنفس أو الكلى أو الكبد أو القلب.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض يسبب لك ضعفًا شديدًا وإرهاقًا ووهنا.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض الوهن العضلي ؛ حيث تشعر بضعف في العضلات.</p><p dir="RTL">&bull; إذا كنت تعاني من متلازمة انقطاع النفس النومي؛ حيث ينقطع التنفس أثناء النوم.</p><p dir="RTL">&bull; إذا كنت قد تعرضت لأي من المشاكل الصحية الناتجة عن تناول الكحوليات.</p><p dir="RTL">&bull; إذا كنت قد تعرضت لأي من المشاكل الصحية الناتجة عن تعاطي المخدرات.</p><p dir="RTL">إذا كان أي من الحالات السابقة تنطبق عليك (أو في حالة عدم التأكد)، يمكنك استشارة طبيبك أو الممرضة الخاصة بك قبل تناول عقار ميداثيتيك.</p><p dir="RTL">الأطفال</p><p dir="RTL">&bull; قم باستشارة طبيبك أو الممرضة الخاصة بك، إذا كان طفلك يعاني من أي من الحالات السابقة.</p><p dir="RTL">&bull; على الأخص، أبلغ طبيبك أو الممرضة الخاصة بك إذا كان طفلك يعاني من مشاكل في القلب أو التنفس.</p><p dir="RTL">الأدوية الأخرى وعقار ميداثيتيك</p><p dir="RTL">قم بإبلاغ طبيبك أو الممرضة الخاصة بك، إذا كنت تتناول (أو قد تناولت مؤخرًا أو قد تتناول مستقبلاً) أي أدوية أخرى، ولا سيما الأدوية التي تبتاعها بدون وصفة طبية والأدوية العشبية؛ حيث إن عقار ميداثيتيك قد يؤثر على طريقة عمل بعض الأدوية الأخرى، فضلاً عن إن بعض الأدوية الأخرى قد تؤثر على طريقة عمل ميداثيتيك.</p><p dir="RTL">وعلى وجه الخصوص، قم بإبلاغ طبيبك أو الممرضة الخاصة بك إذا كنت تتناول أي من الأدوية الآتية:</p><p dir="RTL">&bull; أدوية علاج الاكتئاب (مضادات الاكتئاب)</p><p dir="RTL">&bull; أدوية مُنَوِّمَة (تساعدك على النوم)</p><p dir="RTL">&bull; مهدئات (تساعدك على الشعور بالهدوء والنعاس)</p><p dir="RTL">&bull; الأدوية المهدئة للأعصاب (لعلاج القلق أو لمساعدتك على النوم)</p><p dir="RTL">&bull; كاربامازيبين أو فينيتوين (وتُسْتَخْدَم لعلاج النوبات أو التشنجات)</p><p dir="RTL">&bull; ريفامبيسين (لعلاج السل)</p><p dir="RTL">&bull; فيروس نقص المناعة البشرية</p><p dir="RTL">&bull; أدوية علاج فيروس نقص المناعة البشرية وفيروس الاتهاب الكبدي (ج)، و&quot;مثبطات البروتياز&quot; (مثل: ساكوينافير، بوسيبريفير، تيلابريفير).</p><p dir="RTL">&bull; مضادات حيوية تُعْرَف باسم &quot;ماكروليد&quot; (مثل: إريثروميسين أو كلاريثروميسين).</p><p dir="RTL">&bull; أدوية علاج العدوى الفطرية (مثل: كيتوكونازول، فوريكونازول، فلوكونازول، إيتراكونازول، بوساكونازول).</p><p dir="RTL">&bull; مسكنات قوية للألم.</p><p dir="RTL">&bull; أتورفاستاتين (لعلاج ارتفاع الكوليسترول).</p><p dir="RTL">&bull; مضادات الهيستامين (لعلاج التفاعلات التحسسية).</p><p dir="RTL">&bull; نبتة سانت جون (دواء عشبي لعلاج الاكتئاب).</p><p dir="RTL">&bull; أدوية علاج ارتفاع ضغط الدم والتي تُعْرَف باسم &quot;حاصرات قنوات الكالسيوم&quot; (مثل: ديلتيازيم).</p><p dir="RTL">إذا كان أي من الحالات السابقة تنطبق عليك (أو في حالة عدم التأكد)، يمكنك استشارة طبيبك أو الممرضة الخاصة بك قبل تناول عقار ميداثيتيك.</p><p dir="RTL">كما أن الاستعمال المتزامن لعقار ميداثيتيك مع الأفيونيات (مثل: المسكنات القوية للألم، وأدوية المعالجة الاستبدالية، وبعض أدوية السعال) يعمل على زيادة مخاطر الشعور بالنعاس وضيق التنفس (تثبيط الجهاز التنفسي) والغيبوبة، كما قد يكون مُهَدِّدًا للحياة. ولذا لا ينبغي التفكير في الاستعمال المتزامن إلا عندما لا يكون هناك خيارات بديلة أخرى للعلاج.</p><p dir="RTL">ولكن، إذا وصف لك طبيبك عقار ميداثيتيك مع الأفيونيات، فيجب حينها أن يجعل طبيبك مدة العلاج المتزامن وجرعته محدودة.</p><p dir="RTL">ويُرْجَى إبلاغ طبيبك بكل أدوية الأفيونيات التي تتناولها، واتباع الجرعة التي يُوصِي بها طبيبك بكل دقة. كما سيكون من المفيد إبلاغ الأصدقاء والأقارب ليكونوا على دراية بالعلامات والأعراض المذكورة أعلاه. وقم بالاتصال بطبيبك عند الشعور بتلك الأعراض.</p><p dir="RTL">ميداثيتيك والكحوليات</p><p dir="RTL">لا تشرب أي من الكحوليات إذا كنت قد تناولت عقار ميداثيتيك؛ حيث إنه قد يسبب لك الشعور بالنعاس الشديد، كما قد يسبب لك اضطرابً في التنفس.</p><p dir="RTL">الحمل والإرضاع الطبيعي</p><p dir="RTL">إذا كنتِ حاملاً أو تعتقدين ذلك، يجب عليكِ استشارة طبيبك قبل تناول ميداثيتيك؛ حيث يقرر الطبيب ما إذا كان هذا الدواء مناسبٌ لكِ.</p><p dir="RTL">ويجب على الأمهات بعد تناول عقار ميداثيتيك الامتناع عن إرضاع الطفل لمدة 24 ساعة؛ فربما يكون عقار ميداثيتيك قد تخلل إلى لبن الأم.</p><p dir="RTL">قيادة السيارات واستخدام الآلات</p><p dir="RTL">يجب عليك بعد تناول عقار ميداثيتيك عدم قيادة السيارة أو استعمال الآلات أو الأدوات إلى أن يسمح لك الطبيب بذلك؛ حيث يجعلك عقار ميداثيتيك تشعر بالنعاس والنسيان، كما قد يؤثر على تركيزك و التوافق العضلى. وهذا الأمر قد يؤثر على قدرتك على قيادة السيارات أو استعمال الآلات أو الأدوات. وبعد تلقي العلاج، يجب أن يكون هناك شخصٌ بالغ يرافقك إلى المنزل ويعتني بك.</p><p dir="RTL">قد يؤثر هذا الدواء على قدرتك على قيادة السيارات حيث إنه قد يسبب لك شعورًا بالنعاس أو الدوخة.</p><p dir="RTL">&bull; لا تقم بقيادة السيارة أثناء فترة تناولك هذا الدواء إلى أن تعلم كيفية تأثيره عليك.</p><p dir="RTL">&bull; إذا كان هذا الدواء يؤثر على قدرتك على قيادة السيارة، تُعْتَبَرُ القيادة في هذه الحالة جريمة.</p><p dir="RTL">&bull; ولكنك، لا تُعْتَبَرُ قد ارتكبت جرمًا في الحالة الآتية:</p><p dir="RTL">&bull; إذا كان هذا الدواء قد وُصِفَ لك لعلاج مشكلةٍ ما صحية أو مشكلةٍ في الأسنان</p><p dir="RTL">&bull; إذا كنت قد تناولت هذا العقار طبقًا لتعليمات الطبيب المقرر له وصف العلاج لك أو طبقًا للمعلومات المُقَدَّمَة مع الدواء</p><p dir="RTL">&bull; إذا كان هذا الدواء لا يؤثر على قدرتك على قيادة السيارة بأمان.</p><p dir="RTL">يمكنك التحدث إلى طبيبك أو الصيدلي في حالة عدم التأكد من إمكانيتك لقيادة السيارة بأمان أثناء فترة تناولك هذا العقار.</p><p dir="RTL">احتواء ميداثيتيك على مادة الصوديوم</p><p dir="RTL">يحتوي هذا العقار على كمية قليلة جدا من الصوديوم ؛ أي يمكن القول إنه أساسًا خالٍ من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكنك تناول عقار ميداثيتيك عن طريق طبيب أو ممرضة بحيث تكون بمكانٍ مُجَهَّز بالمعدات اللازمة لمتابعتك وللتعامل مع أي آثار جانبية قد تظهر عليك. وهذا المكان إما أن يكون مستشفى أو عيادة أو حجرة جراحة طبية. وعلى وجه الخصوص، يمكن متابعة حالة التنفس والقلب والدورة الدموية لديك.</p><p dir="RTL">ولا يُنْصَح باستعمال ميداثيتيك مع الأطفال الرُضَّع والأطفال الأقل من 6 أشهر. ولكن إذا رأى الطبيب ضرورة الحالة، يمكن إعطاء هذا العقار للأطفال الرُضَّع أو الأقل من 6 أشهر المحتجزين بالعناية المركزة.</p><p dir="RTL">طريقة استخدام عقار ميداثيتيك</p><p dir="RTL">يمكنك استخدام عقار ميداثيتيك بأي من الطرق الآتية:</p><p dir="RTL">&bull; عن طريق الحقن البطيء في الوريد (حقن وريدي).</p><p dir="RTL">&bull; عن طريق التقطير في أحد الأوردة (التنقيط الوريدي).</p><p dir="RTL">&bull; عن طريق الحقن في عضلة (الحقن العضلي).</p><p dir="RTL">مقدار عقار ميداثيتيك الذي يمكنك تناوله</p><p dir="RTL">تختلف جرعة ميداثيتيك من مريضٍ لآخر. ويقرر الطبيب مقدار الجرعة التي تتناولها؛ حيث يعتمد هذا على العمر والوزن والصحة العامة، كما يعتمد على الغرض الذي تتناول هذا العقار من أجله، ومدى استجابتك للعلاج، وما إذا كنت ستتناول أدوية أخرى في الوقت ذاته.</p><p dir="RTL">بعد تناول ميداثيتيك</p><p dir="RTL">بعد تلقيك العلاج، يجب أن يكون هناك شخص بالغ يرافقك إلى المنزل بحيث يمكنه الاعتناء بك نظرًا لأن هذا العقار قد يسبب لك شعورًا بالنعاس أو النسيان، وقد يؤثر كذلك على تركيزك والتوافق العضلى.</p><p dir="RTL">وإذا كنت ستتناول ميداثيتيك لفترةٍ طويلةٍ كما في وحدة العناية المركزة، قد يبدأ جسمك الاعتياد على هذا العقار، وهذا يعني إنه قد يضعف مفعوله أيضًا.</p><p dir="RTL">إذا تناولت أكثر من الجرعة المطلوبة من عقار ميداثيتيك</p><p dir="RTL">يتم اخذ عقار ميداثيتيك عن طريق الطبيب أو الممرضة، مما يعني إنه لا يُحْتَمَل تناولك جرعة زائدة. ولكن في حالة تناولك أكثر من الجرعة المطلوبة عن طريق الخطأ، قد تلاحظ أي من الأعراض الآتية:</p><p dir="RTL">&bull; الشعور بالنعاس وفقدان قدرتك على التوافق العضلى وردود الأفعال.</p><p dir="RTL">&bull; مشاكل في الكلام وتصبح حركات العين غير اعتيادية.</p><p dir="RTL">&bull; انخفاض ضغط الدم؛ مما يسبب لك شعورًا بالدوخة أو الدوار.</p><p dir="RTL">&bull; بطء أو حتى توقف التنفس أو اختلال ضربات القلب وفقدان الوعي (الغيبوبة).</p><p dir="RTL">استخدام عقار ميداثيتيك لفترة طويلة للتهدئة بوحدة العناية المركزة</p><p dir="RTL">في حالة تناول عقار ميداثيتيك لفترةٍ طويلة، قد يحدث الآتي:</p><p dir="RTL">&bull; قد يقل مفعول هذا العقار.</p><p dir="RTL">&bull; قد تصير معتمدًا على هذا الدواء وتعاني من أعراض الانسحاب عندما تتوقف عن تناوله (انظر &quot;توقف عقار ميداثيتيك&quot; أدناه).</p><p dir="RTL">في حالة التوقف عن استعمال عقار ميداثيتيك</p><p dir="RTL">في حالة تناولك عقار ميداثيتيك لفترةٍ طويلةٍ كما في وحدة العناية المركزة، قد تعاني من أعراض الانسحاب عندما تتوقف عن تناوله.</p><p dir="RTL">ومن بينها:</p><p dir="RTL">&bull; تغيرات مزاجية</p><p dir="RTL">&bull; نوبات صرع (تشنجات)</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; ألم في العضلات</p><p dir="RTL">&bull; مشاكل في النوم (أرق)</p><p dir="RTL">&bull; الشعور بالقلق الشديد، أو التوتر، أو التململ، أو الارتباك، أو سوء المزاج (سرعة الانفعال).</p><p dir="RTL">&bull; رؤية وربما سماع أشياء غير موجودة في الواقع (هلاوس).</p><p dir="RTL">فيقوم طبيبك بخفض الجرعة تدريجيًا، مما يعمل على إيقاف أعراض الانسحاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا العقار بعض الآثار الجانبية، وشأنه في ذلك شأن سائر الأدوية، ولكن ليس بالضرورة أن تحدث مع الجميع. وفيما يلي بعض الآثار الجانبية التالية التي تم الإبلاغ عنها، أما عن مدى تكرارها فهو أمرٌ غير معروف ولا يمكن تقديره من واقع البيانات المتاحة.</p><p dir="RTL">توقف عن تناول عقار ميداثيتيك، وتوجه فورًا إلى الطبيب إذا لاحظتَ أي من الآثار الجانبية التالية. وقد تصل خطورة هذه الآثار الجانبية إلى حد تهديد الحياة؛ مما يتطلب المعالجة الطبية العاجلة:</p><p dir="RTL">&bull; رد فعلٍ تحسسي شديد (صدمة عصبية). ومن بيت هذه العلامات: طفح جلدي مفاجئ، أو حكة، أو طفح جلدي عقدي، تورم الوجه، أو الشفاه، أو اللسان، أو أجزاء أخرى من الجسم. كما قد تعاني من ضيق النفس، أو أزيز، أو مشاكل في التنفس.</p><p dir="RTL">&bull; نوبة قلبية (توقف القلب)، وقد تشمل العلامات أيضًا: ألم الصدر.</p><p dir="RTL">&bull; مشاكل في التنفس، وقد تصل أحيانًا إلى قصور فى النفس.</p><p dir="RTL">&bull; تشنج عضلي حول الحنجرة، مما يؤدي إلى حدوث اختناق.</p><p dir="RTL">وتزيد احتمالية حدوث الآثار الجانبية المهددة للحياة مع كبار السن الذين قد تجاوزوا الستين من عمرهم، وكذا مع الأشخاص الذين يعانون بالفعل من مشاكل في التنفس أو القلب. وأيضًا تزيد احتمالية حدوث هذه الآثار الجانبية إذا تم إجراء الحقن بسرعةٍ عالية أو بجرعةٍ كبيرة.</p><p dir="RTL">آثار جانبية محتملة أخرى</p><p dir="RTL">الجهاز العصبي والاضطرابات الذهنية</p><p dir="RTL">&bull; انخفاض مستوى اليقظة.</p><p dir="RTL">&bull; الشعور بالارتباك.</p><p dir="RTL">&bull; الشعور بالسعادة الزائدة أو الاستثارة (حالة النشوة).</p><p dir="RTL">&bull; تغيرات في الرغبة الجنسية.</p><p dir="RTL">&bull; الشعور بالإرهاق أو النعاس أو الشعور بالخمول لفترةٍ طويلة.</p><p dir="RTL">&bull; رؤية أو ربما سماع أشياء غير موجودة في الواقع (هلاوس).</p><p dir="RTL">&bull; اضطراب الوعي (الهذيان).</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; الشعور بالدوخة</p><p dir="RTL">&bull; صعوبة في توافق العضلات</p><p dir="RTL">&bull; نوبات صرع (تشنجات) لدى الأطفال المبتسرين والأطفال حديثي الولادة.</p><p dir="RTL">&bull; فقدان ذاكرة مؤقت؛ وتعتمد مدة استمرار هذا الفقدان المؤقت للذاكرة على كمية عقار ميداثيتيك التي قد تناولتها، وقد يستمر ذلك في بعض الأحيان لمدة طويلة.</p><p dir="RTL">&bull; الشعور بالهياج أو التململ أو الغضب أو العدوانية.</p><p dir="RTL">&bull; كما قد تشعر بتشنجات عضلية أو ارتجاف عضلاتك بصورة لا إرادية (الرعاش). وتزيد احتمالية حدوث هذه الآثار إذا كنت قد تناولت عقار ميداثيتيك بجرعة كبيرة أو بسرعةٍ عالية. كما تزيد احتمالية حدوث ذلك مع الأطفال وكبار السن.</p><p dir="RTL">القلب والدورة الدموية</p><p dir="RTL">&bull; الإغماء</p><p dir="RTL">&bull; بطء في معدل ضربات القلب</p><p dir="RTL">&bull; احمرار الوجه والرقبة (تورد)</p><p dir="RTL">&bull; انخفاض ضغط الدم، مما قد يجعلك تشعر بالدوخة أو الدوار.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنفس</p><p dir="RTL">&bull; فواق</p><p dir="RTL">&bull; ضيق النفس</p><p dir="RTL">الفم والمعدة والأمعاء</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; إمساك</p><p dir="RTL">&bull; الشعور بالغثيان أو القيء</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد</p><p dir="RTL">&bull; الشعور بالحكة</p><p dir="RTL">&bull; طفح جلدي، ولا سيما الطفح الجلدي العقدي (الشرى)</p><p dir="RTL">&bull; احمرار أو آلام أو تجمعات دموية أو تورم المنطقة التي تم حقنها في الجلد.</p><p dir="RTL">آثار جانبية عامة</p><p dir="RTL">&bull; تفاعلات حساسية مثل الطفح الجلدي والأزيز.</p><p dir="RTL">&bull; تورم الجلد/ الغشاء المخاطي (وذمة وعائية).</p><p dir="RTL">&bull; تزيد مخاطر السقوط والكسور لدى الأشخاص الذين يتناولون مهدئات متزامنة (مثل المشروبات الكحولية).</p><p dir="RTL">&bull; أعراض انسحاب (انظر &quot;التوقف عن استعمال عقار ميداثيتيك&quot; في القسم (3) أعلاه).</p><p dir="RTL">&bull; إدمان العقار.</p><p dir="RTL">كبار السن</p><p dir="RTL">&bull; يُعَدُّ كبار السن الذين يتناولون أدوية البنزوديازيبين مثل ميداثيتيك أكثر عُرْضَة لخطر السقوط وكسر العظام.</p><p dir="RTL">&bull; كما تزيد احتمالية تَعَرُّض كبار السن الذين تتجاوز أعمارهم 60 عام للآثار الجانبية المهددة للحياة.</p><p dir="RTL">الإبلاغ عن الآثار الجانبية</p><p dir="RTL">في حالة الشعور بأي آثار جانبية، يُرْجَى التحدث إلى طبيبك أو الممرضة، وقد يشمل هذا أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الادارة التنفيذية للتيقظ وتقييم المنافع والمخاطر</p><p dir="RTL">الخط الساخن لهيئة الغذاء و الدواء: 19999</p><p dir="RTL">البريد الإلكتروني: NPC.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;الموقع: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">طريقة تخزين ميداثيتيك</p><p dir="RTL">&bull; يُعَدُّ طبيبك أو الصيدلي مسئولًا عن تخزين عقار ميداثيتيك، كما يُعْتَبَرُ مسئولًا عن التخلص من أي عقار ميداثيتيك غير مستخدم بشكلٍ سليم.</p><p dir="RTL">&bull; يًحْفَظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&bull; لا يُسْتَخْدَم هذا الدواء بعد تاريخ انتهاء صلاحيته والموضح على الغلاف الخارجي أو العلبة بعد كلمة &quot;انتهاء الصلاحية:&quot;. ويُشِيرُ تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&bull; لا تستعمل هذا الدواء في حالة تلف الزجاجة الصغيرة (أمبولة)أو العبوة..</p><p dir="RTL">&bull; يخزن في درجة حرارة لا تزيد عن 30 &deg;م</p><p dir="RTL">العمر التخزيني:&nbsp; 3 سنوات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ميداثيتيك 3مللي: تحتوي العلبة الكرتون على ثلاث امبولات زجاجية (النوع الأول) بكل منها 3مللى مع النشرة الدوائية</p><p dir="RTL">ميداثيتيك 1 مللى: تحتوي العلبة الكرتون على امبولة زجاجية واحدة او 10 امبولات (النوع الأول)&nbsp; , بكل منها 1مللى مع النشرة الدوائية</p><p dir="RTL">ملاحظات :</p><p dir="RTL">متوافق مع المحاليل التالية للحقن بنظام التنقيط الوريدى</p><p dir="RTL">-0.9% كلوريد الصوديوم</p><p dir="RTL">-5% دكستروز</p><p dir="RTL">-10% دكستروز</p><p dir="RTL">-رينجر ملحي</p><p dir="RTL">-يجب فحص المحلول بصريا قبل الاعطاء, يجب استخدام المحاليل الخالية من أي جسيمات مرئية.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>N/A</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أمون الدوائية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            N/A
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Midathetic ® Ampoule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each 1ml contains:
- Active substance/substances:
Name of the active substance(s)	     Quantity	   Unit/ Capsule	   Reference/Monograph standard
          Midazolam	                                           5	                  mg	                                     BP

- Name of the excipients(s)	            Quantity	           Unit	            Reference/Monograph standard
Sodium Chloride                                         	8	                    mg	                                        BP
Disodium Edetate	                              0.1	                    mg	                                        BP
HCl (conc.)	                                              0.3	                    mg	                                        BP
Water for injection   to	                        1	                    ml	                                        BP


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ampoule, Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Midathetic is a short-acting sleep-inducing drug that is indicated:</p><p><strong>In adults</strong></p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:98.5pt;margin-top:5.1pt;width:2.75pt;
 height:2.75pt;z-index:-1343;mso-position-horizontal-relative:page'
 coordorigin="1970,102" coordsize="55,55">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1970;top:102;width:55;
  height:55' coordorigin="1970,102" coordsize="55,55" path="m2006,157r-16,l1985,155r-7,-5l1973,145r-3,-7l1970,124r3,-7l1982,107r8,-5l2006,102r5,5l2018,112r5,5l2026,124r,14l2023,145r-5,5l2011,155r-5,2e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="5" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />CONSCIOUS SEDATION, before and during diagnostic or therapeutic procedures with or without local anesthesia</p><p><!--[if gte vml 1]><v:group id="_x0000_s1028" style='position:absolute;
 left:0;text-align:left;margin-left:98.5pt;margin-top:5pt;width:2.75pt;
 height:2.75pt;z-index:-1342;mso-position-horizontal-relative:page'
 coordorigin="1970,100" coordsize="55,55">
 <v:shape id="_x0000_s1029" style='position:absolute;left:1970;top:100;width:55;
  height:55' coordorigin="1970,100" coordsize="55,55" path="m2006,155r-16,l1985,153r-12,-12l1970,134r,-15l1973,112r9,-9l1990,100r16,l2011,103r7,4l2023,112r3,7l2026,134r-3,7l2011,153r-5,2e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><u><img width="5" height="5" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" />ANAESTHESIA :</u></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premedication before induction of anesthesia.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Induction of anesthesia.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As a sedative component in combined anesthesia.</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1030" style='position:absolute;left:0;text-align:left;
 margin-left:98.5pt;margin-top:5.5pt;width:2.75pt;height:2.75pt;z-index:-1341;
 mso-position-horizontal-relative:page' coordorigin="1970,110" coordsize="55,55">
 <v:shape id="_x0000_s1031" style='position:absolute;left:1970;top:110;width:55;
  height:55' coordorigin="1970,110" coordsize="55,55" path="m2006,165r-16,l1985,161r-7,-5l1973,151r-3,-7l1970,129r3,-7l1982,113r8,-3l2006,110r5,3l2018,117r5,5l2026,129r,15l2023,151r-5,5l2011,161r-5,4e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image003.gif" /><u>SEDATION IN INTENSIVE CARE UNITS</u></p><p>&nbsp;</p><p><strong>In children</strong></p><p><!--[if gte vml 1]><v:group id="_x0000_s1032" style='position:absolute;
 left:0;text-align:left;margin-left:98.5pt;margin-top:5.3pt;width:2.75pt;
 height:2.75pt;z-index:-1340;mso-position-horizontal-relative:page'
 coordorigin="1970,106" coordsize="55,55">
 <v:shape id="_x0000_s1033" style='position:absolute;left:1970;top:106;width:55;
  height:55' coordorigin="1970,106" coordsize="55,55" path="m2006,161r-16,l1985,159r-7,-5l1973,149r-3,-7l1970,125r3,-4l1978,113r4,-4l1990,106r16,l2011,109r7,4l2023,121r3,4l2026,142r-3,7l2018,154r-7,5l2006,161e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image004.gif" />CONSCIOUS SEDATION before and during diagnostic or therapeutic procedures with or without local anesthesia</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1034" style='position:absolute;left:0;text-align:left;
 margin-left:98.5pt;margin-top:5.2pt;width:2.75pt;height:2.75pt;z-index:-1339;
 mso-position-horizontal-relative:page' coordorigin="1970,104" coordsize="55,55">
 <v:shape id="_x0000_s1035" style='position:absolute;left:1970;top:104;width:55;
  height:55' coordorigin="1970,104" coordsize="55,55" path="m2006,159r-16,l1985,157r-12,-12l1970,138r,-15l1973,116r9,-9l1990,104r16,l2011,107r7,4l2023,116r3,7l2026,138r-3,7l2011,157r-5,2e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><u><img width="5" height="5" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />ANAESTHESIA</u></p><p>- Premedication before induction of anesthesia</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='position:absolute;left:0;text-align:left;
 margin-left:98.5pt;margin-top:5.4pt;width:2.75pt;height:2.75pt;z-index:-1338;
 mso-position-horizontal-relative:page' coordorigin="1970,108" coordsize="55,55">
 <v:shape id="_x0000_s1037" style='position:absolute;left:1970;top:108;width:55;
  height:55' coordorigin="1970,108" coordsize="55,55" path="m2006,163r-16,l1985,161r-7,-5l1973,149r-3,-5l1970,127r3,-4l1978,115r4,-4l1990,108r16,l2011,111r7,4l2023,123r3,4l2026,144r-3,5l2018,156r-7,5l2006,163e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><u><img width="5" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image003.gif" />SEDATION IN INTENSIVE CARE UNITS</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:311.65pt;margin-top:96.3pt;width:17.8pt;
 height:9.4pt;z-index:-1336;mso-position-horizontal-relative:page'
 coordorigin="6233,1926" coordsize="356,188">
 <v:group id="_x0000_s1027" style='position:absolute;left:6240;top:1953;
  width:120;height:154' coordorigin="6240,1953" coordsize="120,154">
  <v:shape id="_x0000_s1028" style='position:absolute;left:6240;top:1953;
   width:120;height:154' coordorigin="6240,1953" coordsize="120,154" path="m6240,2061r,-12l6338,2005r-98,-43l6240,1953r120,52l6360,2008r-120,53e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:6240;
   top:1953;width:120;height:154' coordorigin="6240,1953" coordsize="120,154"
   path="m6360,2106r-120,l6240,2097r120,l6360,2106e" fillcolor="black"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1030" style='position:absolute;
  left:6374;top:1933;width:94;height:156' coordorigin="6374,1933" coordsize="94,156">
  <v:shape id="_x0000_s1031" style='position:absolute;left:6374;top:1933;
   width:94;height:156' coordorigin="6374,1933" coordsize="94,156" path="m6419,2089r-15,-5l6384,2067r-7,-18l6374,2027r,-14l6403,1957r29,-19l6442,1933r24,l6466,1938r-10,l6446,1941r-4,2l6434,1945r-16,17l6408,1977r-2,7l6401,1991r-3,10l6410,2001r-2,2l6403,2005r-5,5l6396,2020r,29l6398,2056r3,9l6406,2073r7,7l6418,2082r24,l6439,2085r-20,4e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:6374;
   top:1933;width:94;height:156' coordorigin="6374,1933" coordsize="94,156"
   path="m6442,2082r-15,l6434,2077r5,-4l6444,2065r2,-7l6446,2034r-2,-12l6439,2013r-5,-8l6427,2001r-29,l6410,1993r10,-2l6439,1991r10,2l6456,2003r7,7l6468,2022r,12l6465,2053r-10,19l6442,2082e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1033" style='position:absolute;
  left:6487;top:1933;width:93;height:156' coordorigin="6487,1933" coordsize="93,156">
  <v:shape id="_x0000_s1034" style='position:absolute;left:6487;top:1933;
   width:93;height:156' coordorigin="6487,1933" coordsize="93,156" path="m6540,2089r-49,-40l6487,2006r3,-21l6526,1933r19,l6554,1938r2,3l6528,1941r-12,12l6511,1962r,15l6510,1984r-1,17l6509,2027r2,20l6518,2075r8,7l6552,2082r-5,5l6540,2089e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1035" style='position:absolute;left:6487;
   top:1933;width:93;height:156' coordorigin="6487,1933" coordsize="93,156"
   path="m6552,2082r-14,l6552,2068r5,-23l6558,2026r1,-25l6557,1979r-3,-17l6545,1943r-5,-2l6556,1941r11,14l6574,1970r5,20l6581,2015r-2,20l6574,2053r-5,12l6562,2075r-8,5l6552,2082e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="23" height="12" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='position:absolute;left:0;text-align:left;
 margin-left:334.9pt;margin-top:98.7pt;width:24.15pt;height:8.45pt;z-index:-1335;
 mso-position-horizontal-relative:page' coordorigin="6698,1974" coordsize="483,169">
 <v:group id="_x0000_s1037" style='position:absolute;left:6706;top:1984;
  width:110;height:151' coordorigin="6706,1984" coordsize="110,151">
  <v:shape id="_x0000_s1038" style='position:absolute;left:6706;top:1984;
   width:110;height:151' coordorigin="6706,1984" coordsize="110,151" path="m6754,1986r-48,l6706,1984r48,l6754,1986e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1039" style='position:absolute;left:6706;
   top:1984;width:110;height:151' coordorigin="6706,1984" coordsize="110,151"
   path="m6816,1986r-31,l6785,1984r31,l6816,1986e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1040" style='position:absolute;left:6706;
   top:1984;width:110;height:151' coordorigin="6706,1984" coordsize="110,151"
   path="m6755,2113r-13,l6749,2106r5,-9l6761,2080r-39,-77l6722,2001r-4,-5l6715,1991r-2,-2l6708,1986r38,l6744,1989r-2,l6742,1996r4,9l6770,2056r9,l6761,2099r-5,12l6755,2113e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1041" style='position:absolute;left:6706;
   top:1984;width:110;height:151' coordorigin="6706,1984" coordsize="110,151"
   path="m6779,2056r-9,l6794,2001r,-12l6792,1986r19,l6804,1993r-2,5l6802,2003r-23,53e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1042" style='position:absolute;left:6706;
   top:1984;width:110;height:151' coordorigin="6706,1984" coordsize="110,151"
   path="m6730,2135r-10,l6718,2133r-5,-3l6710,2128r,-15l6715,2109r12,l6732,2111r5,l6737,2113r18,l6751,2121r-7,4l6737,2133r-7,2e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1043" style='position:absolute;
  left:6826;top:1981;width:86;height:108' coordorigin="6826,1981" coordsize="86,108">
  <v:shape id="_x0000_s1044" style='position:absolute;left:6826;top:1981;
   width:86;height:108' coordorigin="6826,1981" coordsize="86,108" path="m6881,2089r-24,l6847,2085r-11,-12l6828,2056r-2,-22l6829,2012r9,-16l6847,1986r12,-5l6883,1981r10,3l6898,1989r-39,l6854,1991r-9,10l6842,2005r,10l6912,2015r,7l6842,2022r,15l6845,2049r7,7l6859,2065r10,5l6903,2070r-5,7l6890,2085r-9,4e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1045" style='position:absolute;left:6826;
   top:1981;width:86;height:108' coordorigin="6826,1981" coordsize="86,108"
   path="m6912,2015r-24,l6888,2008r-2,-5l6886,2001r-3,-5l6881,1993r-5,-2l6874,1989r24,l6907,1998r5,12l6912,2015e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1046" style='position:absolute;left:6826;
   top:1981;width:86;height:108' coordorigin="6826,1981" coordsize="86,108"
   path="m6903,2070r-17,l6895,2065r7,-4l6910,2046r2,3l6910,2058r-5,10l6903,2070e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1047" style='position:absolute;
  left:6924;top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108">
  <v:shape id="_x0000_s1048" style='position:absolute;left:6924;top:1981;
   width:94;height:108' coordorigin="6924,1981" coordsize="94,108" path="m6946,2015r-15,l6929,2013r,-12l6931,1993r15,-9l6955,1981r29,l6989,1986r5,3l6955,1989r-7,7l6948,2013r-2,2e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1049" style='position:absolute;left:6924;
   top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108"
   path="m6953,2089r-12,l6936,2087r-10,-10l6924,2070r,-14l6926,2051r,-2l6936,2039r8,-5l6960,2025r22,-8l6982,2003r-3,-7l6977,1993r-3,-4l6994,1989r2,2l7001,2001r,24l6982,2025r-12,4l6962,2032r-2,2l6953,2037r-3,4l6948,2044r-2,5l6943,2051r,10l6948,2070r2,3l6955,2075r22,l6972,2080r-7,5l6962,2085r-9,4e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1050" style='position:absolute;left:6924;
   top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108"
   path="m6941,2017r-5,l6934,2015r9,l6941,2017e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1051" style='position:absolute;left:6924;
   top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108"
   path="m6977,2075r-12,l6972,2070r10,-7l6982,2025r19,l7001,2070r-19,l6977,2075e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1052" style='position:absolute;left:6924;
   top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108"
   path="m7016,2075r-8,l7008,2073r2,l7013,2070r5,-2l7018,2073r-2,2e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1053" style='position:absolute;left:6924;
   top:1981;width:94;height:108' coordorigin="6924,1981" coordsize="94,108"
   path="m7001,2089r-10,l6986,2087r-2,-2l6984,2082r-2,-5l6982,2070r19,l7003,2073r,2l7016,2075r-6,7l7001,2089e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1054" style='position:absolute;
  left:7018;top:1981;width:72;height:106' coordorigin="7018,1981" coordsize="72,106">
  <v:shape id="_x0000_s1055" style='position:absolute;left:7018;top:1981;
   width:72;height:106' coordorigin="7018,1981" coordsize="72,106" path="m7058,2082r-28,l7030,2080r2,-3l7032,1996r-2,l7030,1993r-12,l7049,1981r2,l7051,1993r-29,l7020,1996r31,l7051,2008r5,l7051,2017r,51l7054,2073r,4l7058,2082e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1056" style='position:absolute;left:7018;
   top:1981;width:72;height:106' coordorigin="7018,1981" coordsize="72,106"
   path="m7056,2008r-5,l7061,1989r7,-8l7085,1981r2,5l7090,1989r,9l7063,1998r,3l7058,2003r-2,5e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1057" style='position:absolute;left:7018;
   top:1981;width:72;height:106' coordorigin="7018,1981" coordsize="72,106"
   path="m7085,2008r-5,l7078,2005r-5,-2l7070,1998r20,l7090,2001r-3,2l7087,2005r-2,3e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1058" style='position:absolute;left:7018;
   top:1981;width:72;height:106' coordorigin="7018,1981" coordsize="72,106"
   path="m7063,2085r-41,l7027,2082r34,l7063,2085e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1059" style='position:absolute;left:7018;
   top:1981;width:72;height:106' coordorigin="7018,1981" coordsize="72,106"
   path="m7066,2087r-48,l7018,2085r48,l7066,2087e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1060" style='position:absolute;
  left:7104;top:1981;width:70;height:108' coordorigin="7104,1981" coordsize="70,108">
  <v:shape id="_x0000_s1061" style='position:absolute;left:7104;top:1981;
   width:70;height:108' coordorigin="7104,1981" coordsize="70,108" path="m7159,2082r-14,l7147,2080r5,-3l7154,2075r3,-5l7157,2061r-3,-5l7147,2049r-7,-3l7130,2039r-12,-5l7111,2029r-7,-7l7104,2001r2,-5l7111,1989r7,-5l7126,1981r19,l7150,1984r4,l7157,1986r9,l7166,1989r-40,l7118,1996r,12l7121,2013r2,2l7128,2017r7,5l7150,2029r16,8l7174,2046r,22l7169,2075r-7,5l7159,2082e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1062" style='position:absolute;left:7104;
   top:1981;width:70;height:108' coordorigin="7104,1981" coordsize="70,108"
   path="m7166,1986r-7,l7164,1981r2,l7166,1986e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1063" style='position:absolute;left:7104;
   top:1981;width:70;height:108' coordorigin="7104,1981" coordsize="70,108"
   path="m7166,2015r-2,l7162,2003r-10,-10l7142,1989r24,l7166,2015e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1064" style='position:absolute;left:7104;
   top:1981;width:70;height:108' coordorigin="7104,1981" coordsize="70,108"
   path="m7106,2089r-2,l7104,2056r2,l7111,2070r7,5l7123,2080r7,2l7159,2082r-2,3l7106,2085r,4e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1065" style='position:absolute;left:7104;
   top:1981;width:70;height:108' coordorigin="7104,1981" coordsize="70,108"
   path="m7147,2089r-14,l7123,2087r-7,-2l7157,2085r-3,2l7147,2089e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="32" height="11" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1066" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:364.3pt;margin-top:96.05pt;width:51.45pt;
 height:8.8pt;z-index:-1334;mso-position-horizontal-relative:page'>
 <v:imagedata src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="69" height="12" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image004.gif" />Midathetic is a potent sedative agent that requires titration and slow administration. Titration is strongly recommended to safely obtain the d desired level of sedation according to the clinical need, physical status, age and concomitant medication. In adults over 60 years, debilitated or chronically ill patients and pediatric patients, dose should be determined with caution and risk factors related to each patient should be taken into account. Standard dosages are provided in the table below. Additional details are provided in the text following the table.</p><table border="1" cellspacing="1" cellpadding="1" style="width:833px"><tbody><tr><td style="width:167px">Indication</td><td style="width:191px">Adults &lt;60 years</td><td style="width:207px">Adults&gt;60 years or debilitated or&nbsp;chronically ill</td><td style="width:266px">Children</td></tr><tr><td style="width:167px">Conscious sedation</td><td style="width:191px"><p>I.V.</p><p>Initial dose: 2-2.5 mg</p><p>Titration doses: 1 mg Total dose: 3.5-7.5 mg</p></td><td style="width:207px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>I.V.</p><p>Initial dose: 0.5-1 mg</p><p>Titration doses: 0.5-1 mg Total dose: &lt; 3.5 mg</p></td></tr></tbody></table></td><td style="width:266px"><p><u>- I.V. &nbsp;in &nbsp;patients &nbsp;6 &nbsp;months- 5 years</u> Initial dose: 0.05-0.1 mg/kg . Total dose: &lt;6 mg</p><p><u>- I.V. in patients 6-12 years Initial dose:</u> 0.025-0.05 mg/kg Total dose: &lt; 10 mg</p><p><u>- I.M.&nbsp; 1-15 years</u>&nbsp; &nbsp;0.05-0.15mg/kg</p></td></tr><tr><td style="width:167px">Anesthesia premedication</td><td style="width:191px"><p>I.V. 1-2 mg repeated</p><p>I.M. 0.07- 0.1 mg/kg</p></td><td style="width:207px"><p>I.V. Initial &nbsp;dose: &nbsp;0.5mg. &nbsp;&nbsp;</p><p>Slow uptitration as needed</p><p>I.M.0.025- 0.05 mg/kg</p></td><td style="width:266px">I.M.&nbsp; &nbsp;1-15&nbsp; &nbsp;years&nbsp; &nbsp; 0.08-0.2 mg/kg</td></tr><tr><td style="width:167px">Anesthesia induction</td><td style="width:191px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>I.V.</p><p>0.15- 0.2 mg /kg (0.3-0.35 without premedication)</p></td></tr></tbody></table></td><td style="width:207px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>I.V.</p><p>0.05- 0.15 mg /kg (0.15- 0.3 without premedication)</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table></td><td style="width:266px">&nbsp;</td></tr><tr><td style="width:167px">Sedative component in combined anesthesia</td><td style="width:191px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>I.V.</p><p>intermittent doses of 0.03- 0.1 mg /kg or continuous infusion of 0.03- 0.1 mg/kg/h</p></td></tr></tbody></table></td><td style="width:207px"><p>I.V</p><p>lower&nbsp;doses than recommended for adults &lt;60 years</p></td><td style="width:266px">&nbsp;</td></tr><tr><td style="width:167px"><p>Sedation in ICU</p></td><td style="width:191px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p>I.V.</p><p>Loading dose: 0.03-0.3 mg/ kg in increments of 1- 2.5 mg</p><p>Maintenance dose: 0.03-0.2 mg/kg/h</p></td></tr></tbody></table></td><td style="width:207px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>I.V.</p><p>Loading dose: 0.03-0.3 mg/ kg in increments of 1- 2.5 mg</p><p>Maintenance dose: 0.03-0.2 mg/kg/h</p></td></tr></tbody></table></td><td style="width:266px"><p>-<u> I.V in &nbsp;neonates &nbsp;&lt;32 &nbsp;Weeks gestational age</u> 0.03 mg/kg/h</p><p>- <u>I.V. in neonates &gt;32 weeks and children up to 6 months</u>&nbsp; &nbsp; 0.06 mg/kg/h</p><p><u>- I.V. in patients &nbsp;&gt;6 &nbsp;months &nbsp;of age:</u></p><p>Loading dose: 0.05-0.2 mg/kg</p><p>Maintenance dose: 0.06-0.12 mg/kg/</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>CONSCIOUS SEDATION DOSAGE</strong></p><p>For conscious sedation prior to diagnostic or surgical intervention, Midathetic is administered i.v. The dose must be individualized and titrated, and should not be administered by rapid or single bolus injection.</p><p>The onset of sedation may vary individually depending on the physical status of the patient and the detailed circumstances of dosing (e.g. speed of administration, amount of dose). If necessary, subsequent doses may be administered according to the individual need. The onset of action is about 2 minutes after the injection. Maximum effect is obtained in about 5 to 10 minutes.</p><p>&nbsp;</p><p><strong>Adults</strong></p><p>The IV injection of Midathetic should be given slowly at a rate of approximately 1 mg in 30 seconds.</p><p><!--[if gte vml 1]><v:group id="_x0000_s1067" style='position:absolute;
 left:0;text-align:left;margin-left:115.55pt;margin-top:5.15pt;width:2.5pt;
 height:2.65pt;z-index:-1333;mso-position-horizontal-relative:page'
 coordorigin="2311,103" coordsize="50,53">
 <v:shape id="_x0000_s1068" style='position:absolute;left:2311;top:103;width:50;
  height:53' coordorigin="2311,103" coordsize="50,53" path="m2342,155r-12,l2323,153r-5,-5l2314,141r-3,-5l2311,122r3,-7l2323,105r7,-2l2342,103r8,2l2359,115r3,7l2362,136r-3,5l2354,148r-4,5l2342,155e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="5" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image005.gif" /><u>In adults below the age of 60,</u> the initial dose is 2 to 2.5 mg given 5 to 10</p><p>minutes before the beginning of the procedure. Further doses of 1 mg may be given as necessary. Mean total doses have been found to range from 3.5 to 7.5 mg. A total dose greater than 5 mg is usually not necessary.</p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1069" style='position:absolute;left:0;text-align:left;
 margin-left:115.55pt;margin-top:5.25pt;width:2.5pt;height:2.65pt;z-index:-1332;
 mso-position-horizontal-relative:page' coordorigin="2311,105" coordsize="50,53">
 <v:shape id="_x0000_s1070" style='position:absolute;left:2311;top:105;width:50;
  height:53' coordorigin="2311,105" coordsize="50,53" path="m2342,157r-12,l2323,155r-5,-7l2314,143r-3,-5l2311,124r3,-7l2323,107r7,-2l2342,105r8,2l2359,117r3,7l2362,138r-3,5l2354,148r-4,7l2342,157e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image006.gif" /><u>In adults over 60 years of age</u>, debilitated or chronically ill patients, the initial dose must be reduced to 0.5-1.0 mg and given 5-10 minutes before the</p><p>beginning of the procedure. Further doses of 0.5 to 1 mg may be given as necessary. Since in these patients the peak effect may be reached less rapidly, additional Midathetic should be titrated very slowly and carefully. A total dose greater than 3.5 mg is usually not necessary.</p><p><strong>Children</strong></p><p>I.V. administration: Midathetic should be titrated slowly to the desired clinical effect. The initial dose of Midathetic should be administered over 2 to 3 minutes. One must wait an additional 2 to 5 minutes to fully evaluate the sedative effect before initiating a procedure or repeating a dose. If further sedation is</p><p>necessary, continue to titrate with small increments until the appropriate level of</p><p>sedation is achieved. Infants and young &nbsp;children less than 5 years of age may require substantially higher doses (mg/kg) &nbsp;than older children and adolescents.</p><p><u>Pedi</u><u>a</u><u>t</u><u>r</u><u>i</u><u>c</u><u> </u><u>p</u><u>a</u><u>t</u><u>i</u><u>e</u><u>n</u><u>t</u><u>s</u><u> </u><u>l</u><u>e</u><u>ss</u><u> </u><u>than </u><u>6 months of age:</u> pediatric patients less than 6 months of age are particularly vulnerable to airway obstruction and hypoventilation. For this reason, the use in conscious sedation in children less than 6 months of age is not recommended.<!--[if gte vml 1]><v:group
 id="_x0000_s1073" style='position:absolute;left:0;text-align:left;
 margin-left:115.55pt;margin-top:5.25pt;width:2.5pt;height:2.65pt;z-index:-1330;
 mso-position-horizontal-relative:page' coordorigin="2311,105" coordsize="50,53">
 <v:shape id="_x0000_s1074" style='position:absolute;left:2311;top:105;width:50;
  height:53' coordorigin="2311,105" coordsize="50,53" path="m2342,157r-12,l2323,155r-9,-10l2311,138r,-14l2314,119r4,-7l2323,107r7,-2l2342,105r8,2l2354,112r5,7l2362,124r,14l2359,145r-9,10l2342,157e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><p><u>P</u><u>e</u><u>d</u><u>i</u><u>a</u><u>t</u><u>r</u><u>i</u><u>c</u><u> </u><u>p</u><u>a</u><u>t</u><u>i</u><u>e</u><u>n</u><u>t</u><u>s</u><u> </u><u>6 months to 5 years of age:</u> initial dose 0.05 &nbsp;to 0.1 mg/kg. &nbsp;A total dose up to 0.6 mg/kg may be necessary to reach the desired endpoint, but the total dose should not exceed 6 mg. Prolonged sedation and risk of hypoventilation may be associated with the higher doses.</p><p><u>Pe</u><u>d</u><u>i</u><u>a</u><u>t</u><u>r</u><u>i</u><u>c</u><u> </u><u>p</u><u>a</u><u>t</u><u>i</u><u>e</u><u>n</u><u>t</u><u>s</u><u> </u><u>6 to 12 years of age:</u> initial dose 0.025 &nbsp;to 0.05 &nbsp;mg/kg. &nbsp;A total dose of up to 0.4 mg/kg to a maximum of 10 mg may be necessary. Prolonged sedation and risk of hypoventilation may be associated with the higher doses.</p><p><u>Pe</u><u>d</u><u>i</u><u>a</u><u>t</u><u>r</u><u>i</u><u>c</u><u> </u><u>p</u><u>a</u><u>t</u><u>i</u><u>e</u><u>n</u><u>t</u><u>s</u><u> </u><u>1</u><u>2 to 16 years of age</u>: should be dosed as adults.</p><p>I.M. administration: As IM injection is painful, this rout should only be used in exceptional cases. Rectal administration should be preferred. However, a dose range from 0.08 &nbsp;to 0.2 mg / Kg of Midathetic administered IM has been shown to be effective and safe. In children between ages 1 and 15 years, proportionally higher doses are required than in adults in relation to body-weight.</p><p>the doses used range between 0.05 &nbsp;and 0.15 mg/kg. &nbsp;A total dose greater than</p><p>10.0 &nbsp;mg is usually not necessary. This route should only be used in exceptional cases.</p><p><u>In children, less than 15 kg of body weight, Midathetic solutions with concentrations higher than 1mg/ml are not recommended. Higher concentrations should be diluted to 1mg/ml.</u></p><p><strong>INDUCTION</strong></p><p><strong>Adults</strong></p><p>If Midathetic is used for induction of anesthesia before other anesthetic agents have been administered, the individual response is variable. The dose should be titrated to the desired effect according to the patient&#39;s age and clinical status.</p><p>When Midathetic is used before or in combination with other IV or inhalation agents for induction of anesthesia, the initial dose of each agent should be significantly reduced, at times to as low as 25% of the usual initial dose of the individual agents.</p><p>The desired level of anesthesia is reached by stepwise titration. The IV induction dose of Midathetic should be given slowly in increments.</p><p>Each increment of not more than 5 mg should be injected over 20 to 30 seconds allowing 2 minutes between successive increments.<!--[if gte vml 1]><v:group id="_x0000_s1079" style='position:absolute;
 left:0;text-align:left;margin-left:131.9pt;margin-top:6.75pt;width:2.75pt;
 height:2.75pt;z-index:-1327;mso-position-horizontal-relative:page'
 coordorigin="2638,135" coordsize="55,55">
 <v:shape id="_x0000_s1080" style='position:absolute;left:2638;top:135;width:55;
  height:55' coordorigin="2638,135" coordsize="55,55" path="m2674,190r-15,l2652,185r-10,-9l2638,168r,-14l2642,147r10,-10l2659,135r15,l2681,137r9,10l2693,154r,14l2690,176r-9,9l2674,190e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><p>&nbsp;</p><p>-<img width="5" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image010.gif" />In Premedicated adults below the age of 60 years, an IV dose of 0.15 &nbsp;to 0.2 mg/kg &nbsp;will usually suffice.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1081" style='position:absolute;
 left:0;text-align:left;margin-left:132.5pt;margin-top:5pt;width:2.75pt;
 height:2.75pt;z-index:-1326;mso-position-horizontal-relative:page'
 coordorigin="2650,100" coordsize="55,55">
 <v:shape id="_x0000_s1082" style='position:absolute;left:2650;top:100;width:55;
  height:55' coordorigin="2650,100" coordsize="55,55" path="m2686,155r-17,l2664,153r-12,-12l2650,136r,-17l2652,112r5,-5l2664,102r5,-2l2686,100r4,2l2698,107r4,5l2705,119r,17l2702,141r-12,12l2686,155e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="5" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image011.gif" />- In Non-premedicated adults below the age of 60 the dose may be higher (0.3 to 0.35 &nbsp;mg/kg i.v.). If needed to complete induction, increments of approximately 25% of the patient&#39;s initial dose may be used. Induction may instead be completed with inhalational anesthetics. In resistant cases, a total dose of up to 0.6 mg/kg may be used for induction, but such larger doses may prolong recovery.</p><p>&nbsp;</p><p>In Premedicated adults over 60 years of age, debilitated or chronically ill patients, the dose should significantly be reduced, e.g., down to 0.05- &nbsp;0.15 mg/kg &nbsp;administered i.v. over 20-30 &nbsp;seconds and allowing 2 minutes for effect. Non-premedicated adults over 60 years of age usually require more Midathetic for induction; an initial dose of 0.15 &nbsp;to 0.3 mg/kg is recommended. Nonpremedicated patients with severe systemic disease or other debilitation usually require less Midathetic for induction. An initial dose of 0.15 &nbsp;to 0.25 &nbsp;mg/kg will usually suffice.</p><p>&nbsp;</p><p><strong>SEDATIVE COMPONENT IN COMBINED ANAESTHESIA </strong></p><p><strong>Adults</strong></p><p>Midathetic can be given as a sedative component in combined anesthesia by either further intermittent small i.v. doses (range between 0.03 and 0.1 mg/kg)&nbsp; or continuous infusion of i.v. Midathetic (range between 0.03 &nbsp;and 0.1 mg/kg/h) typically in combination with analgesics. The dose and the intervals between</p><p>In Adults over 60 years of age, debilitated or chronically ill patients, lower maintenance doses will be required.</p><p>&nbsp;</p><p><strong>SEDATION IN INTENSIVE CARE UNITS</strong></p><p>The desired level of sedation is reached by stepwise titration of Midathetic followed by either continuous infusion or intermittent bolus, according to the clinical need, physical status, age and concomitant medication.</p><p><strong>Adults</strong></p><p>I.V. loading dose: 0.03 &nbsp;to 0.3 mg/kg &nbsp;should be given slowly in increments. Each increment of 1 to 2.5 mg should be injected over 20 to 30 seconds allowing 2 minutes between successive increments. In hypovolaemic, vasoconstricted, or hypothermic patients the loading dose should be reduced or omitted.</p><p>When Midathetic is given with potent analgesics, the latter should be</p><p>administered first so that the sedative effects of Midathetic can be safely titrated on top of any sedation caused by the analgesic.</p><p>I.V. maintenance dose: doses can range from 0.03 &nbsp;to 0.2 mg/kg/h. In hypovolaemic, vasoconstricted, or hypothermic patients the maintenance dose should be reduced. The level of sedation should be assessed regularly. With long-term sedation, tolerance may develop and the dose may have to be increased.</p><p><strong>Neonates and children up to 6 months of age:</strong></p><p>&nbsp;</p><p>Midathetic&nbsp;should&nbsp;be given&nbsp;as a continuous&nbsp;i.v.&nbsp;infusion,&nbsp;starting&nbsp;at 0.03 &nbsp;mg/kg/h (0.5&nbsp;&mu;g/kg/min) in neonates witha gestational age &lt;32 weeks, or 0.06 mg/kg/h (1&mu;g/kg/min) in neonates with a gestational age &gt;32 weeks and children up to&nbsp;6 months.</p><p>Intravenous loading doses is not recommended in premature infants, neonates and children up to 6 months, rather the infusion may be run more rapidly for the first several hours to establish therapeutic plasma levels. The rate of infusion should be carefully and frequently reassessed, particularly after the first 24 hours so as to administer the lowest possible effective dose and reduce the potential for drug accumulation.</p><p>Careful monitoring of respiratory rate and oxygen saturation is required.</p><p>&nbsp;</p><p><strong>Children over 6 months of age:</strong></p><p>In intubated and ventilated pediatric patients, a loading dose of 0.05 &nbsp;to 0.2 mg/kg</p><p>I.V. should be administered slowly over at least 2 to 3 minutes to establish the desired clinical effect. Midathetic should not be administered as a rapid intravenous dose. The loading dose is followed by a continuous i.v. infusion at 0.06 to 0.12 mg/kg/h (1 to 2 &mu;g/kg/min). the rate of infusion can be increased or decreased (generally by 25% of the initial or subsequent infusion rate) as required, or supplemental i.v. doses of Midathetic can be administered to increase or maintain the desired effect.</p><p>When initiating an infusion with Midathetic in hemodynamically compromised patients, the usual loading dose should be titrated in small increments and the patient monitored for hemodynamic instability, e.g. hypotension. These patients are also vulnerable to the respiratory depressant effects of Midathetic and require careful monitoring of respiratory rate and oxygen saturation.</p><p>In premature infants, neonates and children less than 15 kg of body weight, Midathetic solutions with concentrations higher than 1mg/ml are not recommended. Higher concentrations should be diluted to 1mg/ml.</p><p>&nbsp;</p><p><u><strong>Special Populations</strong></u></p><p><strong>Renal Impairment</strong></p><p>In patients with renal impairment (creatinine clearance &lt;10ml/min) the pharmacokinetics of unbound Midazolam following a single IV dose is similar to that reported in healthy volunteers. However, after prolonged infusion in intensive care unit (ICU) patients, the mean duration of the sedative effect in the renal failure population (shown after prolonged infusion in intensive care unit (ICU) patients) was considerably increased most likely due to accumulation of <strong>&alpha;</strong>-hydroxy &nbsp;Midazolam glucuronide.</p><p>There is no specific data in patients with severe renal impairment (creatinine clearance below 30 ml/min) receiving Midazolam for induction of anesthesia.</p><p><strong>Hepatic Impairment</strong>​​​​​​​</p><p>Hepatic impairment reduces the clearance of i.v. Midazolam with a subsequent increase in terminal half-life. Therefore, the clinical effects may be stronger and prolonged. The required dose of Midazolam may be reduced and proper monitoring of vital signs should be established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to benzodiazepines or to any of the excipients listed in section.

Use of this drug for conscious sedation in patients with severe respiratory failure or acute respiratory depression.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Midazolam should be administered only by experienced physicians in a setting fully equipped for the monitoring and support of respiratory &nbsp;and cardiovascular function and by persons specifically trained in the recognition and management of expected adverse events including respiratory &nbsp;and cardiac resuscitation.</p><p>Severe cardiorespiratory adverse events have been reported. These have included respiratory depression, apnea, respiratory &nbsp;arrest and/or cardiac arrest. Such life-threatening incidents are more likely to occur when the injection is given too rapidly or when a high dosage is administered.</p><p>Special caution is required for the indication of conscious sedation in patients with impaired respiratory &nbsp;function.</p><p>Pediatric patients less than 6 months of age are particularly vulnerable to airway obstruction and hypoventilation, therefore titration with small increments to clinical effect and careful respiratory &nbsp;rate and oxygen saturation &nbsp;monitoring are essential.</p><p>When Midazolam is used for premedication, adequate observation of the patient after administration is mandatory as interindividual sensitivity varies and symptoms of overdose may occur.</p><p>&nbsp;</p><p><strong>Special caution should be exercised when administering Midazolam to high-risk patients:</strong></p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:99pt;margin-top:7pt;width:2.75pt;height:2.75pt;z-index:-1315;
 mso-position-horizontal-relative:page' coordorigin="1980,140" coordsize="55,55">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1980;top:140;width:55;
  height:55' coordorigin="1980,140" coordsize="55,55" path="m2016,195r-17,l1994,192r-7,-4l1982,183r-2,-7l1980,161r2,-7l1987,149r5,-7l1999,140r17,l2021,142r12,12l2035,161r,15l2033,183r-5,5l2021,192r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><u><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />adults over 60 years of age</u><!--[if gte vml 1]><v:group
 id="_x0000_s1028" style='position:absolute;left:0;text-align:left;
 margin-left:99pt;margin-top:5.25pt;width:2.75pt;height:2.75pt;z-index:-1314;
 mso-position-horizontal-relative:page' coordorigin="1980,105" coordsize="55,55">
 <v:shape id="_x0000_s1029" style='position:absolute;left:1980;top:105;width:55;
  height:55' coordorigin="1980,105" coordsize="55,55" path="m2016,160r-17,l1994,157r-7,-4l1982,145r-2,-4l1980,124r2,-5l1987,112r5,-5l1999,105r17,l2021,107r7,5l2033,119r2,5l2035,141r-2,4l2028,153r-7,4l2016,160e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]-->&nbsp;</p><p><u>chronically ill or debilitated patients</u>, e.g.</p><ul><li>patients with chronic respiratory &nbsp;insufficiency<!--[if gte vml 1]><v:group id="_x0000_s1032" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:5.25pt;width:2.75pt;
 height:2.75pt;z-index:-1312;mso-position-horizontal-relative:page'
 coordorigin="1980,105" coordsize="55,55">
 <v:shape id="_x0000_s1033" style='position:absolute;left:1980;top:105;width:55;
  height:55' coordorigin="1980,105" coordsize="55,55" path="m2016,160r-17,l1994,157r-7,-4l1982,148r-2,-7l1980,126r2,-7l1987,114r5,-7l1999,105r17,l2021,107r12,12l2035,126r,15l2033,148r-5,5l2021,157r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]-->,</li><li>patients with chronic renal failure, impaired hepatic function (benzodiazepines may precipitate or exacerbate encephalopathy in patients with severe hepatic impairment) or with impaired cardiac function<!--[if gte vml 1]><v:group
 id="_x0000_s1034" style='position:absolute;left:0;text-align:left;
 margin-left:99pt;margin-top:5.25pt;width:2.75pt;height:2.75pt;z-index:-1311;
 mso-position-horizontal-relative:page' coordorigin="1980,105" coordsize="55,55">
 <v:shape id="_x0000_s1035" style='position:absolute;left:1980;top:105;width:55;
  height:55' coordorigin="1980,105" coordsize="55,55" path="m2016,160r-17,l1994,157r-7,-4l1982,148r-2,-7l1980,126r2,-7l1987,114r5,-7l1999,105r17,l2021,107r12,12l2035,126r,15l2033,148r-5,5l2021,157r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]-->&nbsp;</li></ul><p><u>pediatric patients</u> especially those with cardiovascular instability.</p><p>&nbsp;</p><p>These high-risk patients require lower dosages and should be continuously monitored for early signs of alterations of vital functions.</p><p>As with any substance with CNS depressant and/or muscle-relaxant properties, particular &nbsp;care should be taken when administering Midazolam to a patient with myasthenia gravis.</p><p>&nbsp;</p><p><strong>Tolerance</strong></p><p>Some loss of efficacy has been reported when Midazolam was used as long-term sedation in intensive care units (ICU).</p><p><strong>Dependence</strong></p><p>When Midazolam is used in long-term sedation in ICU, it should be borne in mind that physical dependence on Midazolam may develop. The risk of dependence increases with dose and duration of treatment; it is also greater in patients with a medical history of alcohol and/or drug abuse.</p><p><strong>Withdrawal Symptoms</strong></p><p>During prolonged treatment with Midazolam in ICU, physical dependence may develop. Therefore, abrupt termination of the treatment will be accompanied by withdrawal symptoms. The following symptoms may occur: headaches, muscle pain, anxiety, tension, restlessness, confusion, irritability, rebound insomnia, mood changes, hallucinations and convulsions. Since the risk of withdrawal symptoms is greater after abrupt discontinuation of treatment, it is recommended to decrease doses gradually.</p><p><strong>Amnesia</strong></p><p>Midazolam causes anterograde amnesia (frequently this effect is very desirable in situations such as before and during surgical and diagnostic procedures), the duration of which is directly related to the administered dose. Prolonged amnesia can present problems in outpatients, who are scheduled for discharge following intervention. After receiving Midazolam parenterally, patients should be discharged from hospital or consulting room only if accompanied by an attendant.</p><p><strong>Paradoxical reactions</strong></p><p>Paradoxical reactions such as agitation, involuntary movements (including tonic/clonic convulsions and muscle tremor), hyperactivity, hostility, rage reaction, aggressiveness, paroxysmal excitement and assault, have been reported to occur with Midazolam. These reactions may occur with high doses and/or when the injection is given rapidly. The highest incidence to such reactions has been reported among children and the elderly. if these events occur, discontinuation of treatment should be considered.</p><p><strong>Altered elimination of Midazolam</strong></p><p>Midazolam elimination may be altered in patients receiving compounds that inhibit or induce CYP3A4 and the dose of Midazolam may need to be adjusted accordingly. Midazolam elimination may also be delayed in patients with liver dysfunction, low cardiac output and in neonates.</p><p><strong>Sleep Apnea</strong></p><p>Midazolam ampoules should be used with extreme caution in patients with sleep apnea syndrome and these patients should be monitored regularly.</p><p><strong>Preterm infants and neonates:</strong></p><p>Due to an increased risk of apnea, extreme caution is advised when sedating preterm and former preterm non-intubated patients. Careful monitoring of respiratory &nbsp;rate and oxygen saturation &nbsp;is required.</p><p><strong>Rapid injection should be avoided in the neonatal population.</strong></p><p>Neonates have reduced and/or immature organ function and are also vulnerable to profound and/or prolonged respiratory &nbsp;effects of Midazolam.</p><p>Adverse hemodynamic events have been reported in pediatric patients with cardiovascular instability; rapid intravenous administration should be avoided in this population.</p><p><strong>Pediatric patients less than 6 months:</strong></p><p>In this population, Midazolam is indicated for sedation in ICU only. Pediatric patients less than 6 months of age are particularly &nbsp;vulnerable to airway obstruction and hypoventilation, therefore titration with small increments to clinical effect and careful respiratory &nbsp;rate and<!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='position:absolute;left:0;text-align:left;
 margin-left:374.75pt;margin-top:2pt;width:110.9pt;height:11.05pt;z-index:-1310;
 mso-position-horizontal-relative:page' coordorigin="7495,40" coordsize="2218,221">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="_x0000_s1037" type="#_x0000_t75" style='position:absolute;
  left:7495;top:40;width:1527;height:221'>
  <v:imagedata src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image004.png"
   o:title=""/>
 </v:shape><v:group id="_x0000_s1038" style='position:absolute;left:9074;top:105;
  width:110;height:103' coordorigin="9074,105" coordsize="110,103">
  <v:shape id="_x0000_s1039" style='position:absolute;left:9074;top:105;
   width:110;height:103' coordorigin="9074,105" coordsize="110,103" path="m9103,208r-12,l9086,206r-9,-10l9074,191r,-9l9100,127r34,-22l9146,105r5,2l9154,110r-17,l9132,112r-5,5l9118,124r-8,10l9106,146r-8,12l9096,170r,19l9101,191r2,5l9125,196r-10,7l9110,206r-7,2e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1040" style='position:absolute;left:9074;
   top:105;width:110;height:103' coordorigin="9074,105" coordsize="110,103"
   path="m9180,122r-19,l9166,110r19,-5l9180,122e" fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1041" style='position:absolute;left:9074;
   top:105;width:110;height:103' coordorigin="9074,105" coordsize="110,103"
   path="m9125,196r-19,l9113,195r14,-7l9147,167r7,-19l9156,129r,-12l9154,114r-5,-2l9146,110r8,l9158,112r3,5l9161,122r19,l9163,177r-17,l9130,193r-5,3e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1042" style='position:absolute;left:9074;
   top:105;width:110;height:103' coordorigin="9074,105" coordsize="110,103"
   path="m9154,208r-10,l9144,206r-2,l9142,191r2,-7l9146,177r17,l9161,184r-3,10l9158,198r10,l9163,203r-9,5e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1043" style='position:absolute;left:9074;
   top:105;width:110;height:103' coordorigin="9074,105" coordsize="110,103"
   path="m9168,198r-5,l9163,196r5,-5l9173,184r2,2l9170,194r-2,4e" fillcolor="black"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1044" style='position:absolute;
  left:9192;top:47;width:94;height:161' coordorigin="9192,47" coordsize="94,161">
  <v:shape id="_x0000_s1045" style='position:absolute;left:9192;top:47;width:94;
   height:161' coordorigin="9192,47" coordsize="94,161" path="m9233,208r-19,l9202,203r-10,-7l9226,76r2,-7l9228,59r-2,-2l9214,57r,-5l9250,47r-22,79l9235,126r-7,5l9226,138r-5,10l9209,198r5,3l9221,203r25,l9242,206r-9,2e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1046" style='position:absolute;left:9192;
   top:47;width:94;height:161' coordorigin="9192,47" coordsize="94,161" path="m9235,126r-7,l9235,117r5,-5l9254,105r15,l9274,107r4,7l9281,117r-36,l9240,119r-5,7e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1047" style='position:absolute;left:9192;
   top:47;width:94;height:161' coordorigin="9192,47" coordsize="94,161" path="m9246,203r-16,l9238,201r4,-5l9250,191r4,-7l9259,172r5,-10l9266,150r,-19l9264,126r-2,-2l9259,119r-5,-2l9281,117r2,2l9286,126r,22l9283,160r-7,12l9271,182r-9,9l9246,203e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1048" style='position:absolute;
  left:9300;top:105;width:98;height:103' coordorigin="9300,105" coordsize="98,103">
  <v:shape id="_x0000_s1049" style='position:absolute;left:9300;top:105;
   width:98;height:103' coordorigin="9300,105" coordsize="98,103" path="m9346,208r-20,l9317,206r-7,-8l9300,184r,-22l9305,153r5,-12l9317,129r7,-7l9336,114r10,-7l9355,105r19,l9384,107r2,3l9367,110r-9,l9345,119r-15,24l9324,162r-2,20l9322,189r4,9l9329,201r5,2l9358,203r-3,3l9346,208e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1050" style='position:absolute;left:9300;
   top:105;width:98;height:103' coordorigin="9300,105" coordsize="98,103"
   path="m9358,203r-10,l9358,196r9,-17l9371,171r6,-20l9379,131r,-7l9374,114r-2,-2l9367,110r19,l9389,114r7,8l9398,129r,21l9396,162r-5,10l9384,184r-7,10l9365,198r-7,5e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1051" style='position:absolute;
  left:9413;top:105;width:94;height:103' coordorigin="9413,105" coordsize="94,103">
  <v:shape id="_x0000_s1052" style='position:absolute;left:9413;top:105;
   width:94;height:103' coordorigin="9413,105" coordsize="94,103" path="m9413,119r,-7l9446,105r3,5l9451,117r-33,l9413,119e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1053" style='position:absolute;left:9413;
   top:105;width:94;height:103' coordorigin="9413,105" coordsize="94,103"
   path="m9466,189r-8,l9468,177r7,-7l9490,148r2,-2l9494,141r,-3l9497,136r,-5l9494,129r,-5l9485,119r-3,-2l9482,112r5,-5l9490,107r2,-2l9497,105r5,2l9506,112r,17l9504,136r-2,5l9494,150r-4,8l9482,170r-12,12l9470,184r-4,5e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1054" style='position:absolute;left:9413;
   top:105;width:94;height:103' coordorigin="9413,105" coordsize="94,103"
   path="m9446,208r-4,-11l9440,170r-2,-21l9435,132r-3,-10l9427,117r24,l9454,122r,9l9456,141r,9l9458,158r,31l9466,189r-20,19e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1055" style='position:absolute;
  left:9514;top:105;width:86;height:103' coordorigin="9514,105" coordsize="86,103">
  <v:shape id="_x0000_s1056" style='position:absolute;left:9514;top:105;
   width:86;height:103' coordorigin="9514,105" coordsize="86,103" path="m9545,208r-12,l9526,206r-10,-15l9514,184r,-19l9557,107r9,-2l9586,105r9,5l9566,110r-7,4l9542,131r-4,12l9535,158r24,l9547,160r-14,2l9533,179r2,5l9545,194r5,2l9573,196r-12,8l9545,208e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1057" style='position:absolute;left:9514;
   top:105;width:86;height:103' coordorigin="9514,105" coordsize="86,103"
   path="m9559,158r-14,l9552,155r7,-5l9566,148r8,-5l9576,136r5,-5l9583,126r,-9l9581,114r,-2l9578,112r-2,-2l9595,110r3,2l9600,117r,9l9598,134r-12,12l9578,150r-12,5l9559,158e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1058" style='position:absolute;left:9514;
   top:105;width:86;height:103' coordorigin="9514,105" coordsize="86,103"
   path="m9573,196r-9,l9574,191r7,-5l9588,179r-9,13l9573,196e" fillcolor="black"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1059" style='position:absolute;
  left:9581;top:52;width:81;height:202' coordorigin="9581,52" coordsize="81,202">
  <v:shape id="_x0000_s1060" style='position:absolute;left:9581;top:52;width:81;
   height:202' coordorigin="9581,52" coordsize="81,202" path="m9581,254r8,-10l9603,230r13,-16l9641,159r9,-59l9650,93r-3,-19l9638,52r9,8l9654,79r5,19l9662,114r,25l9640,196r-40,44l9581,254e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1061" style='position:absolute;
  left:9691;top:186;width:14;height:22' coordorigin="9691,186" coordsize="14,22">
  <v:shape id="_x0000_s1062" style='position:absolute;left:9691;top:186;
   width:14;height:22' coordorigin="9691,186" coordsize="14,22" path="m9706,189r-10,l9698,186r5,l9706,189e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1063" style='position:absolute;left:9691;
   top:186;width:14;height:22' coordorigin="9691,186" coordsize="14,22" path="m9706,208r-10,l9691,203r,-12l9694,189r14,l9713,194r,7l9706,208e"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]-->&nbsp; oxygen saturation monitoring are essential ( see also section &quot;<strong>Preterm infants&quot; </strong>above)</p><p><strong>Concomitant use of alcohol / CNS depressants:</strong></p><p>The concomitant use of Midazolam with alcohol or/and CNS depressants should be avoided. Such concomitant use has the potential to increase the clinical effects of Midazolam possibly including severe sedation or clinically relevant respiratory depression.</p><p><strong>Risk from concomitant use of opioids:</strong></p><p>Concomitant use of Midazolam Baxter 5 mg/ml solution for injection/infusion and opioids may result in sedation, respiratory &nbsp;depression, coma and death. Because of these risks, concomitant prescribing of sedative medicines such as benzodiazepines or related drugs such as Midazolam Baxter 5 mg/ml solution for injection/infusion with opioids should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Midazolam Baxter 5 mg/ml solution for injection/infusion concomitantly with opioids, the lowest effective dose should be used, and the duration of treatment should be as short as possible.</p><p>The patients should be followed closely for signs and symptoms of respiratory &nbsp;depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers (where applicable) to be aware of these symptoms.</p><p><strong>Medical history of alcohol or drug abuse:</strong></p><p>Midazolam as other benzodiazepines should be avoided in patients with a medical history of alcohol or drug abuse.</p><p><strong>Discharging criteria</strong></p><p>After receiving Midazolam, patients should be discharged from hospital or consulting room only when recommended by treating physician and if accompanied by an attendant. It is recommended that the patient is accompanied when returning home after discharge.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per ampoule, i.e. essentially &quot;<em> Sodium Free&quot;</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Midazolam is metabolized by CYP3A4. Inhibitors and inducers of CYP3A have the potential to respectively increase and decrease the plasma concentrations and, subsequently, the effects of Midazolam thus requiring dose adjustments accordingly.</p><p>Pharmacokinetic interactions with CYP3A4 inhibitors or inducers are more pronounced for oral as compared to i.v. Midazolam, since CYP3A4 also exists in the upper gastro-intestinal tract. This is because for the oral route both systemic clearance and availability will be altered while for the parenteral route only the change in the systemic clearance becomes effective.</p><p>After a single dose of i.v. Midazolam, the consequence on the maximal clinical effect due to CYP3A4 inhibition will be minor while the duration of effect may be prolonged. However, after prolonged dosing of Midazolam, both the magnitude and duration of effect will be increased in the presence of CYP3A4 inhibition.</p><p>There are no available studies on CYP3A4 modulation on the pharmacokinetics of Midazolam after rectal and intramuscular &nbsp;administration. It is expected that these interactions will be less pronounced for the rectal than for the oral route because the gastro-intestinal &nbsp;tract is by-passed whereas after i.m. administration the effects of CYP3A4 modulation should not substantially differ from those seen with i.v.</p><p>Midazolam.</p><p>It is therefore recommended to carefully monitor the clinical effects and vital signs during the use of Midazolam, taking into account that they may be stronger and last longer after co- administration of a CYP3A4 inhibitor, be it given only once. Notably, administration of high doses or long-term infusions of Midazolam to patients receiving strong CYP3A4 inhibitors, e.g. during intensive care, may result in long lasting hypnotic effects, delayed recovery and respiratory &nbsp;depression, thus requiring dose adjustments.</p><p>With respect to induction, it should be considered that the inducing process needs several days to reach its maximum effect and also several days to dissipate. Contrary to a treatment of several days with an inducer, a short-term treatment is expected to result in less apparent DDI with Midazolam. However, for strong inducers a relevant induction even after short-term treatment cannot be excluded.</p><p>Midazolam is not known to change the pharmacokinetics of other drugs.</p><p>&nbsp;</p><p><strong>Drugs that inhibit CYP3A</strong></p><p><u>Azole Antifungals</u><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:7pt;width:2.75pt;height:2.75pt;
 z-index:-1309;mso-position-horizontal-relative:page' coordorigin="1980,140"
 coordsize="55,55">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1980;top:140;width:55;
  height:55' coordorigin="1980,140" coordsize="55,55" path="m2016,195r-17,l1994,192r-7,-4l1982,183r-2,-7l1980,161r2,-7l1992,144r7,-4l2016,140r5,4l2028,149r5,5l2035,161r,15l2033,183r-5,5l2021,192r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><ul><li>Ketoconazole increased the plasma concentrations of intravenous Midazolam by 5-fold while the terminal half-life increased by about 3-fold. If parenteral Midazolam is co- administered with the strong CYP3A inhibitor ketoconazole, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory &nbsp;depression and/or prolonged sedation. Staggered dosing and dosage adjustment should be considered, especially if more than a single i.v. dose of Midazolam is administered. The same recommendation may apply also for other azole antifungals (see further), since increased sedative effects of i.v. Midazolam, although lesser, are reported.<!--[if gte vml 1]><v:group id="_x0000_s1028" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:5.2pt;width:2.75pt;
 height:2.75pt;z-index:-1308;mso-position-horizontal-relative:page'
 coordorigin="1980,104" coordsize="55,55">
 <v:shape id="_x0000_s1029" style='position:absolute;left:1980;top:104;width:55;
  height:55' coordorigin="1980,104" coordsize="55,55" path="m2016,159r-17,l1994,157r-7,-5l1982,147r-2,-7l1980,126r2,-7l1987,114r5,-7l1999,104r17,l2021,107r12,12l2035,126r,14l2033,147r-5,5l2021,157r-5,2e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></li><li>Voriconazole increased the exposure of intravenous Midazolam by 3-fold whereas its elimination half-life increased by about 3-fold.</li><li>Fluconazole and itraconazole both increased the plasma concentrations of intravenous Midazolam by 2 -3-fold associated with an increase in terminal half-life by 2.4-fold for itraconazole and 1.5-fold for fluconazole, respectively.</li><li>Posaconazole increased the plasma concentrations of intravenous Midazolam by about 2-fold.</li><li>It should be kept in mind that if Midazolam is given orally, its exposure will drastically be higher than the above-mentioned ones, notably with ketoconazole, itraconazole, voriconazole.</li></ul><p>Midathetic ampoules are not indicated for oral administration.</p><p><strong>Macrolide antibiotics</strong></p><ul><li>Erythromycin resulted in an increase in the plasma concentrations of intravenous Midazolam by about 1.6-2-fold associated with an increase of the terminal half-life of Midazolam by 1.5-1.8-fold.</li><li>Clarithromycin increased the plasma concentrations of Midazolam by up to 2.5- fold associated with an increase in terminal half-life by 1.5-2-fold.</li><li>Roxithromycin: While no information on roxithromycin with i.v Midazolam is available, the mild effect on the terminal half-life of oral Midazolam tablet, increasing by 30%, indicates that the effects of roxithromycin on intravenous Midazolam may be minor.</li></ul><p><strong>HIV Protease inhibitors</strong><!--[if gte vml 1]><v:group id="_x0000_s1050" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:7.05pt;width:2.75pt;
 height:2.75pt;z-index:-1297;mso-position-horizontal-relative:page'
 coordorigin="1980,141" coordsize="55,55">
 <v:shape id="_x0000_s1051" style='position:absolute;left:1980;top:141;width:55;
  height:55' coordorigin="1980,141" coordsize="55,55" path="m2016,196r-17,l1994,193r-7,-4l1982,184r-2,-7l1980,162r2,-7l1992,145r7,-4l2016,141r5,4l2028,150r5,5l2035,162r,15l2033,184r-5,5l2021,193r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><ul><li>Saquinavir and other HIV protease inhibitors: Co-administration with protease inhibitors may cause a large increase in the concentration of Midazolam. Upon co- administration with ritonavir-boosted lopinavir, the plasma concentrations of intravenous Midazolam increased by 5.4-fold, associated with a similar increase in terminal half-life. If parenteral Midazolam is coadministered with HIV protease inhibitors, treatment setting should follow the description in the above section for azole antifungals, ketoconazole.</li></ul><p><strong>Additional information from oral Midathetic</strong></p><p>Based on data for other CYP3A4 inhibitors, plasma concentrations of Midazolam are expected to be significantly higher when Midazolam is given orally. Therefore, protease inhibitors should not be co-administered with orally administered Midazolam.</p><p><strong>Calcium channel blockers</strong></p><ul><li>Diltiazem: A single dose of diltiazem administered to patients undergoing coronary artery bypass surgery increased the plasma concentrations of intravenous Midazolam by about 25% and the terminal half-life was prolonged by 43%.This is less than the 4-fold increase observed after oral administration of Midazolam.</li><li>Verapamil &nbsp;increased the plasma concentrations of oral Midazolam by 3- fold, respectively. The terminal- half-life of Midazolam was increased by 41% respectively.</li></ul><p><strong>Various drugs/Herbal &nbsp;preparations</strong></p><ul><li><!--[if gte vml 1]><v:group id="_x0000_s1056" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:7pt;width:2.75pt;height:2.75pt;
 z-index:-1294;mso-position-horizontal-relative:page' coordorigin="1980,140"
 coordsize="55,55">
 <v:shape id="_x0000_s1057" style='position:absolute;left:1980;top:140;width:55;
  height:55' coordorigin="1980,140" coordsize="55,55" path="m2016,195r-17,l1994,192r-7,-4l1982,180r-2,-4l1980,159r2,-5l1987,147r5,-5l1999,140r17,l2021,142r7,5l2033,154r2,5l2035,176r-2,4l2028,188r-7,4l2016,195e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />Atorvastatin showed a 1.4-fold increase in plasma concentrations of i.v. Midazolam compared to control group.</li><li><!--[if gte vml 1]><v:group
 id="_x0000_s1058" style='position:absolute;left:0;text-align:left;
 margin-left:99pt;margin-top:5.25pt;width:2.75pt;height:2.75pt;z-index:-1293;
 mso-position-horizontal-relative:page' coordorigin="1980,105" coordsize="55,55">
 <v:shape id="_x0000_s1059" style='position:absolute;left:1980;top:105;width:55;
  height:55' coordorigin="1980,105" coordsize="55,55" path="m2016,160r-17,l1994,157r-7,-4l1982,148r-2,-7l1980,126r2,-7l1987,114r5,-7l1999,105r17,l2021,107r12,12l2035,126r,15l2033,148r-5,5l2021,157r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image012.gif" />Intravenous fentanyl is a weak inhibitor of Midazolam elimination: it increased by 1.5 times the AUC and half-life of Midazolam I.V.</li><li><!--[if gte vml 1]><v:group id="_x0000_s1060" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:7pt;width:2.75pt;height:2.75pt;
 z-index:-1292;mso-position-horizontal-relative:page' coordorigin="1980,140"
 coordsize="55,55">
 <v:shape id="_x0000_s1061" style='position:absolute;left:1980;top:140;width:55;
  height:55' coordorigin="1980,140" coordsize="55,55" path="m2016,195r-17,l1994,192r-7,-4l1982,183r-2,-7l1980,161r2,-7l1987,149r5,-7l1999,140r17,l2021,142r12,12l2035,161r,15l2033,183r-5,5l2021,192r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />Nefazodone increased the plasma concentrations of oral Midazolam by 4.6-fold with an increase of its terminal half-life by 1.6-fold.</li><li><!--[if gte vml 1]><v:group
 id="_x0000_s1062" style='position:absolute;left:0;text-align:left;
 margin-left:99pt;margin-top:5.35pt;width:2.75pt;height:2.75pt;z-index:-1291;
 mso-position-horizontal-relative:page' coordorigin="1980,107" coordsize="55,55">
 <v:shape id="_x0000_s1063" style='position:absolute;left:1980;top:107;width:55;
  height:55' coordorigin="1980,107" coordsize="55,55" path="m2016,162r-17,l1994,159r-12,-12l1980,140r,-14l1982,119r10,-10l1999,107r17,l2021,109r7,5l2033,119r2,7l2035,140r-2,7l2021,159r-5,3e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="4" height="4" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image013.gif" />Aprepitant dose dependently increased the plasma concentrations of oral Midazolam by 3.3-fold after 80 mg/day associated with an increase in terminal half-life by approximately. 2- fold.</li></ul><p><strong>Drugs that induce CYP3A</strong></p><ul><li>Rifampicin decreased the plasma concentrations of intravenous Midazolam by about 60% after 7 days of rifampicin 600mg o.d. The terminal half-life decreased by about 50-60%.</li><li>Ticagrelor is a weak CYP3A inducer but has only a small effect on intravenous Midazolam (-12%) and 4-hydroxy-Midazolam (-23%) exposures.</li><li>Rifampicin decreased the plasma concentrations of oral Midazolam by 96% in healthy subjects and its psychomotor effects were almost totally lost.</li><li>Carbamazepine / phenytoin: Repeat dosages of carbamezepine or phenytoin resulted in a decrease in plasma concentrations of oral Midazolam by up to 90% and a shortening of the terminal half-life by 60%.<!--[if gte vml 1]><v:group id="_x0000_s1072" style='position:absolute;
 left:0;text-align:left;margin-left:99pt;margin-top:5.2pt;width:2.75pt;
 height:2.75pt;z-index:-1286;mso-position-horizontal-relative:page'
 coordorigin="1980,104" coordsize="55,55">
 <v:shape id="_x0000_s1073" style='position:absolute;left:1980;top:104;width:55;
  height:55' coordorigin="1980,104" coordsize="55,55" path="m2016,159r-17,l1994,157r-12,-12l1980,137r,-14l1982,116r10,-10l1999,104r17,l2021,106r7,5l2033,116r2,7l2035,137r-2,8l2021,157r-5,2e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></li><li>The very high induction of CYP3A4 observed after administration of mitotane or enzalutamide resulted in a significant and lasting decrease in Midazolam levels in cancer patients. AUC of oral Midazolam was reduced to 5% and 14%, respectively, of normal values.</li><li>Clobazam and efavirenz are weak inducers of Midazolam metabolism and reduce the AUC of the parent compound by approximately 30%. This results in a 4-5fold increase in the<!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1076" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:97.9pt;margin-top:2.35pt;width:90.05pt;
 height:10.95pt;z-index:-1284;mso-position-horizontal-relative:page'>
 <v:imagedata src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image014.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]-->&nbsp;active metabolite (<strong>&alpha;-</strong>hydroxy Midazolam) ratio on the parent molecule, but the clinical relevance of this increase is not known.</li><li>Vemurafenib modulates CYP isoenzymes and slightly inhibits CYP3A4: repeated administration resulted in an average 32% decrease in oral Midazolam exposure (up to 80% in some individuals).</li></ul><p><strong>Herbs and food</strong></p><ul><li>St John&rsquo;s Wort decreased plasma concentration of Midazolam by about 30 - 40 % associated with a decrease in terminal half-life of about 15 - 17%. Depending on the specific St&nbsp;John&rsquo;s Wort extract, the CYP 3A4-inducing effect may vary.</li><li>Quercetin (also present in Gingko biloba) and Panax ginseng both have low enzyme- inducing effects and lead to a 20-30% reduction in Midazolam exposure after oral administration.</li></ul><p><strong>Acute displacement of proteins</strong></p><p>* Valproic acid: An increase in the concentration of free Midazolam due to the displacement of plasma protein binding sites by valproic acid cannot be ruled out even if the clinical relevance of such interaction is not known.</p><p>&nbsp;</p><p><u><strong>Pharmacodynamic &nbsp;Drug-Drug Interactions (DDI)</strong></u></p><p>The co-administration of Midathetic with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory &nbsp;depression.</p><p>Examples include opiate derivatives (be they used as analgesics, antitussives or substitutive treatments), antipsychotics, other benzodiazepines used as anxiolytics or hypnotics, barbiturates, propofol, ketamine, etomidate; sedative antidepressants, &nbsp;non recent H1- antihistamines and centrally acting antihypertensive drugs.</p><p>Alcohol may markedly enhance the sedative effect of Midathetic. Alcohol intake should be strongly avoided in case of Midathetic administration.</p><p>Midazolam decreases the minimum alveolar concentration (MAC) of inhalational &nbsp;anesthetics.</p><p><strong>Opioids:</strong></p><p>The concomitant use of sedative medicines such as benzodiazepines or related drugs such as Midazolam with opioids increases the risk of sedation, respiratory &nbsp;depression, coma and death because of additive CNS depressant effect. The dosage and duration of concomitant use should be limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insufficient data are available on Midazolam to assess its safety during pregnancy. Animal studies do not indicate a teratogenic effect, but fetotoxicity was observed as with other benzodiazepines. No data on exposed pregnancies are available for the first two trimesters of pregnancy.</p><p>The administration of high doses of Midazolam in the last trimester of pregnancy, during labor or when used as an induction agent of anesthesia for caesarean section has been reported to produce maternal or fetal adverse effects (inhalation risk in mother, irregularities in the fetal heart rate, hypotonia, poor sucking, hypothermia and respiratory &nbsp;depression in the neonate).</p><p>Moreover, infants born from mothers who received benzodiazepines chronically during the latter stage of pregnancy may have developed physical dependence and may be at some risk of developing withdrawal symptoms in the postnatal period.</p><p>Consequently, Midathetic may be used during pregnancy if clearly necessary but it is preferable to avoid using it for caesarean.</p><p>The risk for neonate should be taken into account in case of administration of Midathetic for any surgery near the term.</p><p><strong>Breast-feeding</strong></p><p>Midazolam passes in low quantities into breast milk. Nursing mothers should be advised to discontinue breast-feeding for 24 hours following administration of Midathetic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sedation, amnesia, impaired attention and impaired muscular function may adversely affect the ability to drive or use machines. Prior to receiving Midathetic, the patient should be warned not to drive a vehicle or operate a machine until completely recovered. The physician should decide when these activities may be resumed. It is recommended that the patient is accompanied when returning home after discharge. In cases of insufficient sleep or alcohol consumption, the likelihood of impaired alertness may be increased</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been reported (frequency not known, cannot be estimated from the available data) to occur when Midazolam is injected:</p><p>Frequency categories are as follows:</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:130.5pt;height:11.25pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'>
 <v:imagedata src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image007.png"
  o:title=""/>
</v:shape><![endif]-->Very common:&nbsp;&ge;&nbsp;1/10&nbsp;,&nbsp; Common:&nbsp;&ge;&nbsp;1/100 to &lt;1/100 ,&nbsp; Uncommon:&nbsp;&ge;1/1000 to &lt;1/100 ,&nbsp;</p><p>Rare: (&ge;1/10,000 to &lt;1/1000) , Very rare (&lt;1/10,000) ,&nbsp;Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="1" cellpadding="1" style="width:730px"><tbody><tr><td style="width:334px"><strong>Immune system disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">Frequency not known</td><td style="width:394px">-Hypersensitivity, angioedema, anaphylactic shock</td></tr><tr><td style="width:334px"><strong>Psychiatric Disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px"><p>-Confusional state, euphoric mood, hallucinations</p><p>-Agitation*, hostility*, rage reaction*, aggressiveness*, excitement*</p><p>-Physical drug dependence and withdrawal symptom Abuse</p></td></tr><tr><td style="width:334px"><strong>Nervous system disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px"><p>-Involuntary movements (including tonic/clonic movements and muscle tremor) *, hyperactivity*</p><p>-Sedation (prolonged and postoperative), alertness decreased, somnolence, headache, dizziness, ataxia, anterograde amnesia**, the duration of which is directly related to the administered dose</p><p>-Convulsions have been reported in premature infants and neonates</p><p>-Drug withdrawal convulsions</p></td></tr><tr><td style="width:334px"><strong>Cardiac disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Cardiac arrest, bradycardia</td></tr><tr><td style="width:334px"><strong>Vascular disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Hypotension, vasodilation, thrombophlebitis, thrombosis</td></tr><tr><td style="width:334px"><strong>Respiratory Disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Respiratory depression, apnea, respiratory arrest, dyspnea, laryngospasm, hiccups</td></tr><tr><td style="width:334px"><strong>Gastrointestinal Disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Nausea, vomiting, constipation, dry mouth</td></tr><tr><td style="width:334px"><strong>Skin and Subcutaneous Tissue Disorders</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Rash, urticaria, pruritus</td></tr><tr><td style="width:394px"><strong>General Disorders and Administration Site Conditions</strong></td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Fatigue, injection site erythema, injection site pain</td></tr><tr><td style="width:334px"><strong>Injury, Poisoning and&nbsp;Procedural Complications</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Falls, fractures***</td></tr><tr><td style="width:334px"><strong>Social Circumstances</strong></td><td style="width:394px">&nbsp;</td></tr><tr><td style="width:334px">frequency not known</td><td style="width:394px">Assault*</td></tr></tbody></table><p><strong>*&nbsp;</strong>Such paradoxical drug reactions have been reported, particularly among children and the elderly.</p><p><strong>**&nbsp;</strong>Anterograde amnesia may still be present at the end of the procedure and in few cases prolonged amnesia has been reported..</p><p><strong>***&nbsp;</strong>There have been reports of falls and fractures in benzodiazepine users. The risk of falls and fractures is increased in those taking concomitant sedatives (including alcoholic beverages) and in the elderly.</p><p>&nbsp;</p><p><strong>Dependence: </strong>Use of Midazolam - even in therapeutic doses - may lead to the development of physical dependence. After prolonged i.v. administration, discontinuation, especially abrupt discontinuation of the product, may be accompanied by withdrawal symptoms including withdrawal convulsions. Cases of abuse have been reported.</p><p>Severe cardiorespiratory adverse events have occurred. Life-threatening incidents are more likely to occur in adults over 60 years of age and those with pre-existing respiratory insufficiency or impaired cardiac function, particularly when the injection is given too rapidly or when a high dosage is administered.</p><p><strong>Reporting of suspected &nbsp;adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via :</p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>Email: NPC.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>Like other benzodiazepines, Midazolam commonly causes drowsiness, ataxia, dysarthria and nystagmus. Overdose of Midazolam is seldom life-threatening if the drug is taken alone, but may lead to areflexia, apnea, hypotension, cardiorespiratory depression and in rare cases to coma. Coma, if it occurs, usually lasts a few hours but it may be more protracted and cyclical, particularly in elderly patients. Benzodiazepine respiratory depressant effects are more serious in patients with respiratory disease.</p><p><u>Benzodiazepines increase the effects of other central nervous system depressants, including alcohol.</u></p><p><strong>Treatment</strong></p><p>clinical state. Patients may require symptomatic treatment for cardiorespiratory effects or</p><p>central nervous system effects.</p><p><u>If taken orally further absorption should be prevented using an appropriate method</u></p><p>e.g. treatment within 1-2 hours with activated charcoal. If activated charcoal is used airway protection is imperative for drowsy patients. In case of mixed ingestion gastric lavage may be considered, however not as a routine measure.</p><p><u>If CNS depression is severe consider the use of flumazenil, a benzodiazepine antagonist.</u></p><p>This should only be administered under closely monitored conditions. It has a short half-life (about an hour), therefore patients administered flumazenil will require monitoring after its effects have worn off. Flumazenil is to be used with extreme caution in the presence of drugs that reduce seizure threshold (e.g. tricyclic antidepressants). Refer to the prescribing information for flumazenil, for further information on the correct use of this drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong></p><p>Hypnotics and sedatives: benzodiazepine derivatives,</p><p>Midathetic has hypnotic and sedative effects characterized by rapid onset and short duration. It also has anxiolytic, anticonvulsant and muscle relaxant effects. Midathetic causes impaired psychomotor function after single and / or repeated doses, but causes minimal hemodynamic changes.</p><p>The central actions of benzodiazepines are mediated by an increase in GABAergic neurotransmission at inhibitory synapses. In the presence of benzodiazepines, the affinity of the GABA receptor for the neurotransmitter is enhanced by positive allosteric modulation resulting in increased action of released GABA on the postsynaptic transmembrane flow of the chlorine ions.</p><p>Midazolam is a derivative of the imidazobenzodiazepine group. The free base is a lipophilic substance with low solubility in water.</p><p>The basic nitrogen in position 2 of the imidazobenzodiazepine ring system enables the active ingredient of Midazolam to form water-soluble salts with acids. These produce a stable and well tolerated injection solution.</p><p>Associated with rapid metabolic transformation, this explains the rapid onset and short duration of effects. Due to its low toxicity, Midazolam has a wide therapeutic range.</p><p>After i.m. or i.v. administration anterograde amnesia of short duration occurs (the patient does not remember events that occurred during the maximal activity of the compound).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption after i.m. injection</strong></p><p>Absorption of Midathetic from the muscle tissue is rapid and complete. Maximum plasma concentrations are reached within 30 minutes. The absolute bioavailability after i.m. injection is over 90%.</p><p><strong>Distribution</strong></p><p>When Midathetic is injected i.v., the plasma concentration-time curve shows one or two distinct phases of distribution. The volume of distribution at steady state is 0.7 - 1.2 l/kg.</p><p>96 - 98% of Midazolam is bound to plasma proteins. The major fraction of plasma protein binding is due to albumin. There is a slow and insignificant passage of Midazolam into the cerebrospinal fluid. In humans, Midazolam has been shown to cross the placenta slowly and to enter fetal circulation. Small quantities of Midazolam are found in human milk. &nbsp;Midazolam is not a substrate for drug carriers.</p><p><strong>Biotransformation</strong></p><p>Midazolam is almost entirely eliminated by biotransformation. The fraction of the dose extracted by the liver has been estimated to be 30 - 60%. Midazolam is hydroxylated by the cytochrome P4503A4 isozyme and the major urinary and plasma metabolite is alpha-hydroxy Midazolam. Plasma concentrations of alpha hydroxy Midazolam are 12% of those of the parent compound.</p><p>Alphahydroxy Midazolam is pharmacologically active, but contributes only minimally (about 10%) to the effects of intravenous Midazolam. Elimination</p><p>In healthy volunteers, the elimination half-life of Midazolam is between 1.5 - 2.5 hours. The elimination half-life of the metabolite is less than 1 hour; therefore, after administration of Midazolam, the concentration of the parent compound and that of the main metabolite decrease in parallel. Plasma clearance is in the range of 300 - 500ml/min. Midazolam is excreted mainly by renal route (60 - 80% of the injected dose) and recovered as glucuroconjugated alpha- hydroxy Midazolam. Less than 1% of the dose is recovered in urine as unchanged drug. The elimination half-life of alpha hydroxy-Midazolam is shorter than 1 hour.</p><p>When Midazolam is given by i.v. infusion, its elimination kinetics do not differ from those following bolus injection. Repeated administration of Midazolam does not induce the enzymes of drug metabolism.</p><p>&nbsp;</p><p><u><strong>Pharmacokinetics in special populations</strong></u></p><p><strong>Elderly</strong></p><p>In adults over 60 years of age, the elimination half-life may be prolonged up to four times.</p><p><strong>Children</strong></p><p>The elimination half-life after i.v. administration is shorter in children 3 - 10 years old (1 - 1.5 hours) as compared with that in adults. The difference is consistent with an increased metabolic clearance in children.</p><p><strong>Neonates</strong></p><p>In neonates, the elimination half-life is on average 6 - 12 hours, probably due to liver immaturity and the clearance is reduced. Neonates with hepatic and renal insufficiency associated with asphyxia present a risk of unusually high serum concentrations of Midazolam due to significantly reduced and variable clearance.</p><p><strong>Obese</strong></p><p>The mean half-life is greater in obese than in non-obese patients (5.9 vs 2.3 hours). This is due to an increase of approximately 50% in the volume of distribution corrected for total body weight. The clearance is not significantly different in obese and non-obese patients.</p><p><strong>Patients with hepatic impairment</strong></p><p>The elimination half-life in cirrhotic patients may be longer and the clearance smaller as compared to those in healthy volunteer.</p><p><strong>Patients with renal impairment</strong></p><p>The pharmacokinetics of unbound Midazolam are unaffected in patients with severe renal impairment. The major pharmacologically inactive metabolite of Midazolam, the glucuronide conjugated 1&#39;-hydroxyMidazolam, which is excreted by the kidneys, accumulates in patients with severe renal impairment. This accumulation produces prolonged sedation. Midazolam should be administered with caution and titrated until the desired effect is achieved.</p><p><strong>Critically ill patients</strong></p><p>The elimination half-life of Midazolam is prolonged up to six times in the critically ill. Patients with cardiac insufficiency</p><p>The elimination half-life is longer in patients with congestive heart failure compared with that in healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Ampoule content</u></p><p>- Sodium Chloride</p><p>-&nbsp;Disodium Edetate</p><p>-&nbsp;HCl (conc.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be diluted with other solutions for parenteral use than those mentioned in section 6.6. Instructions for use/handling.</p><p>Compatibility must be checked before administration, if intended to be mixed with other drugs. Midazolam precipitates in solutions containing bicarbonate. Theoretically, the midazolam injection solution is likely to be unstable in solutions of neutral or alkaline pH. If midazolam is mixed with albumin, amoxicillin sodium, ampicillin sodium, bumetanide, dexamethasone sodium phosphate, dimenhydrinate, floxacillin sodium, furosemide, hydrocortisone sodium succinate, pentobarbital sodium, perphenazine, prochlorperazine edisylate, ranitidine or thiopental sodium or trimethoprim-sulfamethoxazole, a white precipitate forms immediately.</p><p>A haze is formed immediately followed by a white precipitate with nafcillin sodium. With ceftazidime a haze is formed.</p><p>With methotrexate sodium a yellow precipitate forms. With clonidine hydrochloride an orange discoloration forms. With omeprazole sodium a brown discoloration forms, followed by a brown precipitate. With foscarnet sodium a gas is produced.</p><p>Further midazolam should not be mixed with aciclovir, albumin,&nbsp; &nbsp;alteplase, acetazolam disodium, diazepam, enoximone, flecainide acetate, fluorouracil, imipenem, mezlocillin sodium, phenobarbital sodium, phenytoin sodium, potassium canrenoate, sulbactam sodium, theophylline, trometamol, urokinase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

After Dilution Shelf Life: 3 Days

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stored at temperature not exceeding 30&deg;C</p><p>&nbsp;</p><p>After Dilution shelf life &amp; Storage condition:</p><p>&nbsp;</p><p>*Solution remains physically &nbsp;and chemically stable for 24 hours at room temperature, or 3 days at 5 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Midathetic 3 ml:</p><p>Carton Box contains 3 amber glass ampoules (Type I), each of 3 ml with insert leaflet</p><p>For Midathetic 1 ml:</p><p>Carton Box contains 1 or 10 amber glass ampoules (Type I) , each of 1 ml with insert leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:98.15pt;margin-top:26.85pt;width:6pt;height:.1pt;z-index:-1277;
 mso-position-horizontal-relative:page' coordorigin="1963,537" coordsize="120,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1963;top:537;width:120;
  height:2' coordorigin="1963,537" coordsize="120,0" path="m1963,537r120,e"
  filled="f" strokeweight=".7pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="10" height="2" src="file:///C:\Users\ssafyan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" />Compatible with the following solutions for infusion:</p><p>- 0.9% NaCl</p><p>- 5% Dextrose</p><p>- 10% Dextrose</p><p>- Ringer Saline</p><p>*Solution remains physically and chemically stable for 24 hours at room temperature, or 3 days at 5 &deg;C.</p><p>The solution for injection should be examined visually before administration. Only solutions without visible particles should be used.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amoun Pharmaceutical Company

El Obour City, Cairo, Egypt. Tel. no: +202 46140100

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                29/04/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>